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  ABSTRACT OF DISSERTATION 
 
 
 
 
FUNCTIONAL CHARACTERIZATION OF SCAFFOLD PROTEIN SHOC2 
 
Signaling scaffolds are critical for the correct spatial organization of enzymes 
within the ERK1/2 signaling pathway and proper transmission of intracellular 
information. However, mechanisms that control molecular dynamics within scaffolding 
complexes, as well as biological activities regulated by the specific assemblies, remain 
unclear.  
 
The scaffold protein Shoc2 is critical for transmission of the ERK1/2 pathway 
signals. Shoc2 accelerates ERK1/2 signaling by integrating Ras and RAF-1 enzymes into 
a multi-protein complex. Germ-line mutations in shoc2 cause Noonan-like RASopathy, a 
disorder with a wide spectrum of developmental deficiencies. However, the physiological 
role of Shoc2, the nature of ERK1/2 signals transduced through this complex or 
mechanisms regulating the function of Shoc2 remain largely unknown. My dissertation 
addresses the mechanisms by which Shoc2 accelerates ERK1/2 signal transmission and 
the biological outputs of the Shoc2-guided signals. 
 
To delineate Shoc2-mediated ERK1/2 signals, I have utilized a vertebrate 
zebrafish model. I demonstrated that loss of Shoc2 protein expression leads to early 
embryonic lethality resulting from a significant reduction in the number of circulating 
erythropoietic and myelopoietic blood cells, underdeveloped neurocranial and pharyngeal 
cartilages, and a profound delay in calcification of bone structures. Together, this data 
demonstrates that the Shoc2 scaffolding module transmits ERK1/2 signals in neural crest 
development and blood cell differentiation.  
 
This dissertation also addresses the mechanistic basis of how allosteric 
ubiquitination of Shoc2 and RAF-1 is controlled. I have characterized a molecular 
interaction of Shoc2 with its previously unknown binding partner Valosin-Containing 
Protein (VCP/p97).  These studies demonstrated that hexametric ATPase VCP modulates 
ubiquitination of Shoc2 and RAF-1 through the remodeling of the scaffolding complex in 
a spatial-restricted manner. Experiments utilizing fluorescence microscopy and 
biochemical methods show that VCP/p97 sequesters the E3 ligase HUWE1 from the 
 Shoc2 module, thereby altering the ubiquitination of Shoc2 and RAF-1 as well as the 
amplitude of ERK1/2 signals. These studies also show that the levels of Shoc2 
ubiquitination and ERK1/2 phosphorylation are imbalanced in fibroblasts isolated from 
Inclusion Body Myopathy with Paget’s disease of bone and Frontotemporal Dementia 
(IBMPFD) patients harboring VCP germline mutations.  This data also suggests that 
ERK1/2 pathway deregulation is part of IBMPFD pathogenesis. 
 
In summary, these studies make a significant advance in our understanding of the 
mechanisms by which the Shoc2 scaffold regulates specificity and the dynamics of the 
ERK1/2 signaling networks. They also make important insights into our understanding of 
biological activities and targets of Shoc2-mediated ERK1/2 signals at the early stages of 
embryonic development and disease. 
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CHAPTER 1 
 
 
Introduction 
 
 
1. The Extracellular-Signal-Regulated Kinases 1/2 (ERK1/2) signaling cascade 
 
The ERK1/2 (or mitogen-activated protein kinase, MAPK) signaling cascade is a 
canonical signaling pathway that converts extracellular cues into an intracellular signals 
that regulate a wide range of cellular processes [1, 2]. The molecular events linking cell 
surface receptors to ERK1/2 activation are well studied. Receptor tyrosine kinases (RTKs) 
such as epidermal growth factor receptor (EGFR) activate the ERK1/2 pathway upon 
ligand  binding [3]. The binding of the ligand to the receptor induces dimerization and auto-
phosphorylation of the receptor, which is followed by the recruitment of the cytosolic 
adaptor proteins such as growth-factor-receptor-bound protein 2 (Grb2) to the plasma 
membrane [4]. Grb2 is bound constitutively to the GTP activating protein (GAP) Son of 
Sevenless (Sos) [5]. The binding of the Grb2-Sos complex to EGFR results in the activation 
of the small Ras GTPases (K-, H-, N- and M-Ras), recruitment of serine/threonine-specific 
protein kinase RAF (RAF-1, B-RAF or A-RAF) to the plasma membrane that leads to 
phosphorylation of MEK (MEK1 and MEK2), and further transmission of the signal via 
the ERK1/2 cascade (Figure 1.1) [6]. The ERK1/2 kinases are the main effectors of the 
cascade. ERK1/2 phosphorylate a plethora of substrates in various locations including the 
nucleus, cytosol, and the plasma membrane [7]. Currently, about 200 distinct ERK1/2 
substrates that are involved in cell proliferation, differentiation, survival, and apoptosis 
have been reported  [7].  
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Figure 1.1 Mechanism of ERK1/2 activation.   
The RAF-MEK-ERK cascade is a three-tiered core signaling component. In brief, signaling 
is initiated when extracellular ligands (growth factors and cytokines) bind to growth factor 
receptors (e.g. EGFR) at the plasma membrane. The activated receptor transmits the signal 
by recruiting the adaptor protein Grb2 and guanine nucleotide exchange factor Sos that, in 
turn, induces the activation of Ras at the plasma membranes. The activated GTP-bound 
Ras then transmits the signal by activating the protein kinase RAF (RAF-1, B-RAF, and 
A-RAF). This activation occurs by recruiting RAFs to the plasma membrane, where they 
are then phosphorylated and activated. The activated RAF phosphorylates MEK1/2, which 
in turn phosphorylates ERK1/2. Phosphorylated ERK1/2 then activates multiple 
downstream targets, including nuclear, cytosolic, membrane-associated, and cytoskeletal 
substrates. 
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2. ERK1/2 signal specificity determination 
The ability of the ERK1/2 cascade to regulate a large number of distinct, and 
sometime opposing cellular processes requires mechanisms that control specificity of 
signals transmitted via the cascade. Factors that determine signal specificity include; (1) 
duration and strength of the signals; (2) subcellular compartmentalization; (3) extensive 
cross-talk and interplay between the ERK cascade and other intracellular signaling 
pathways [8-16].  
 
 2.1 Duration and strength of the signals 
The duration and amplitude of ERK1/2 activity is a key factor in cell fate decisions 
[9]. The activation of the ERK1/2 cascade upon extracellular stimulation may last between 
15 minutes (transient activation) and 2 to 3 hours (sustained activation). For instance, both 
EGF and nerve growth factor (NGF) induce strong activation of the ERK1/2 cascade in 
PC12 cells but the outcomes are distinct [17]. EGF stimulation provokes a rapid and 
transient activation of ERK1/2 that reaches the maximum at 15 min and then returns down 
to basal levels after 40 min, leading to cell proliferation. In contrast, NGF induces a swift 
monophasic ERK1/2 response that is followed by a sustained second phase leading to cell 
differentiation [18, 19]. Murphy et al. demonstrated that this difference in cell response 
could be interpreted as an activation of immediate early genes (i.e. c-Fos, c-Jun, c-Myc and 
Egr1) that induce distinct cellular processes dependent on the signal length [20, 21]. Studies 
also have shown that duration and strength of ERK1/2 signals are influenced by specialized 
interacting proteins, action of protein phosphatases, and chromatin remodeling affects [2, 
7, 9, 10, 16, 21]. 
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2.2 Subcellular compartmentalization 
Spatial segregation of ERK1/2 signals can also define the specificity of the ERK1/2 
signals [22]. In resting cells, the components of the ERK1/2 cascade are localized to the 
cytosol owing to their interaction with specialized anchors or scaffold proteins (these 
proteins are discussed separately in this chapter). Upon activation of the pathway, a portion 
of the activated ERK1/2 residing in the cytosol phosphorylate targets such as ribosomal S6 
kinase (RSK) family proteins and cytoskeletal proteins (i.e. neurofilaments and paxillin) 
[7]. The other portion of ERK1/2 are released from the cytoplasmic anchors and translocate 
into the nucleus or to other subcellular organelles (i.e. mitochondria, endosomes, Golgi 
apparatus, endoplasmic reticulum) [23-26]. The nucleus-localized ERK1/2 phosphorylate 
transcription factors that regulate the expression of immediate early genes [1]. Several 
studies reported that nuclear ERK1/2 phosphorylate substrates mainly responsible for cell 
proliferation, differentiation, and survival [7]. Shortly after stimulation, MEK1/2 are 
exported from the nucleus by the exportin system, while active ERKs stay in the nucleus 
longer, possibly due to interaction with newly synthesized nuclear anchors [23, 27-29]. 
Nucleocytoplasmic shuttling of MEK1/2 also induces an export of ERK1/2 from the 
nucleus, bringing the signaling back to the basal level [30]. Overall, differential subcellular 
distribution of activated ERK1/2 enhances the complexity of the ERK1/2 cascade and 
constitutes an essential mechanism to provide variability to its signals, thereby enabling 
their participation in the regulation of a broad variety of functions [31].  
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2.3 Crosstalk with other signaling cascades 
 Additionally, the specificity of ERK1/2 signals is also achieved via interplay of 
ERK1/2 with other signaling cascades. Although the Ras-RAF-MEK-ERK signaling 
pathway is often presented as a simple linear unidirectional cascade, signals actually 
propagate through an interwoven network of interconnected events rather than through 
independent linear routes [32-34]. Thus, other signaling pathways such as JNK and p38 
regulate the activity of components in several tiers of the ERK1/2 cascade and modify 
activation of these components upon distinct physiological conditions [1]. Signaling 
components of different signaling cascades can either positively or negatively regulate each 
other, and thereby significantly influence the specificity of the signals [33]. This 
connectivity is generally referred to as “signaling crosstalk”.   
 
3. The ERK1/2 pathway in human diseases 
Somatic mutations in the genes of the ERK1/2 pathway or deregulation of ERK1/2 
activity leads to a number of human pathologies, including developmental and 
neurodegenerative diseases, diabetes or cancer [35-38]. The involvement of the ERK1/2 
pathway in cancer pathogenesis is well-documented and has been studied extensively [35, 
36]. The “activating” mutations in genes of the ERK1/2 pathway are responsible for over 
half of all diagnosed cancers [35, 36, 39-48]. Mutations in the B-RAF gene drive about 60% 
of malignant melanomas, colorectal, thyroid, and non-small lung cancers, and are often 
found in patients with hairy cell leukemia [39, 40, 43, 44, 47-51]. Similarly, K-Ras 
mutations are common in leukemias, colorectal, peritoneal, bladder, pancreatic and lung 
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cancers [41]. Aberrations in genes of other Ras and RAF isoforms (A-RAF, RAF-1, H-Ras, 
and N-Ras) are also found in cancers but are less prevalent [52].   
A different group of inherited mutations in the genes of the ERK1/2 pathway cause 
a number of congenital diseases cumulatively called RASopathies. RASopathies are 
estimated to affect about 1/1000 human births [53]. Individuals with these conditions are 
characterized by pleiotropic phenotypes including craniofacial dysmorphisms, heart 
defects, poor growth with skeletal abnormalities, variable degrees of intellectual disability, 
neurocognitive impairment, relative macrocephaly, and increased risk for certain 
malignancies [37, 54, 55]. Each of the RASopathy syndromes has a set of unique 
characteristics, but individuals with distinct mutations share morphological and behavior 
phenotypes [37, 38, 53, 55]. To date, hundreds of mutations have been described by 
molecular and genetic studies and more continue to be added. The germline RASopathies 
identified so far are shown in Figure 1.2.  
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Figure 1.2 The Ras/ERK1/2 signaling pathway and associated RASopathies. 
Proteins commonly mutated in RASopathies are indicated by the dashed lines. The 
Ras/ERK1/2 pathway proteins with germline mutations in their respective genes are 
associated with Noonan syndrome (NS), Noonan syndrome with multiple lentigines 
(NSML), Noonan syndrome with loose anagen hair (NSLH), Neurofibromatosis type 1 
(NF1), Costello syndrome (CS), Legius syndrome (LS), and Cardio-facio-cutaneous 
syndrome (CFC). EGFR- Epidermal growth factor receptor. 
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4. The regulatory mechanism in ERK1/2 signaling cascade 
As mentioned previously (section 2.2), the ERK1/2 cascade is regulated by 
several distinct scaffold proteins [1, 2, 15, 22, 29, 56]. Scaffolds tether signaling proteins 
into a close proximity, target complexes to a particular cellular location, and coordinate 
positive/negative feedback mechanisms (Figure 1.3). In this manner, scaffold proteins 
modulate kinetics of signaling cascade activation, modify duration and intensity of 
transmitted signals, secure interactions between distinct signaling components, regulate 
the localization of the components of the cascade, or modify crosstalk with other 
signaling pathways [10, 15, 22, 56-59]. In summary, scaffolds support several 
mechanisms that can independently determine signaling specificity, and therefore, are 
key components in the signaling cascades [1, 2, 15, 16, 22, 29, 56, 58, 59]. 
The importance of the scaffold proteins in ERK1/2 signaling was demonstrated 
when prototypic scaffold Ste5 was shown to bind to multiple components of the 
Saccharomyces cerevisiae mating pheromone response pathway, thereby conducting the 
mating signal to the Fus3 kinase [58, 60-65]. Ste5 integrates the three-tiered core ERK1/2 
signaling components Fus3, Ste7, and Ste11 and increases their local concentration at the 
tips of mating projections in response to mating pheromones [58, 60, 61, 63-67]. The 
signals transmitted through the Ste5 complex initiate cellular processes necessary for 
mating, including transcriptional activation of mating-specific genes, cell-cycle arrest in 
G1 phase, polarized growth, and cell fusion [58, 61, 63]. 
Over the past decade, several studies have demonstrated that scaffold proteins are 
critical for regulating of the ERK1/2 cascade in mammals. The mechanisms by which the 
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key scaffolds modulate duration, strength, activity, or cellular distribution of signals 
within the ERK1/2 pathway are briefly reviewed below (Figure 1.3). 
           
              (A)                                 (B) 
 
 
               (C)                                       (D) 
 
Figure 1.3 Properties of scaffold proteins. Scaffold proteins can hold more than two 
molecules and allow an efficient signal transduction (A), focus the signaling activity at a 
particular site of action (B), integrate both positive and negative signaling components 
(C), mediate feedback mechanisms, coordinate allosteric modification of signaling 
molecules, and regulate stability of the signaling components (D).  
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 4.1 Kinase Suppressor of Ras (KSR)  
One of the best-studied scaffolds of the ERK1/2 pathway is Kinase Suppressor of Ras 
1 and 2 (KSR1 and 2) [68, 69]. Identified in genetic screens performed in Drosophila 
melanogaster (D. melanogaster) and Caenorhabditis elegans (C. elegans), KSR1 is a 
positive regulator of Ras pathway signaling [68-70]. KSR1 facilitates MEK 
phosphorylation by RAF-1, leading to increased ERK1/2 activation [69, 71-75]. In 
quiescent cells, KSR1 is associated with MEK1/2 and 14-3-3. In response to EGFR 
activation, dephosphorylated KSR1 releases 14-3-3 and translocates to the plasma 
membrane. At the plasma membrane, KSR1 facilitates MEK1/2 activation via assembly 
of Ras and RAF-1 complexes [71]. Loss or overexpression of KSR1 in cells alters the 
degree to which ERK1/2 are activated [1, 69, 72-74, 76-79].  
Genetic studies in mammalian systems demonstrated that KSR1 knockout mice are 
fertile and phenotypically and developmentally normal [75]. Ksr1-/- mice presented with 
attenuated ERK1/2 activation and marginally impaired immunological response 
(particularly in regards to T-cell activation). Interestingly, KSR1 knockouts were found 
to be resistant to Ras-driven tumors with subsequent studies showing that KSR1 is 
required for the complete oncogenic potential of Ras-driven cancer cells [75, 80].  
Even though KSR1 and KSR2 are structurally similar, KSR2 has a distinct 
physiological role in regulating energy balance [78, 81]. Ksr2-/-  knockout mice have 
reduced fertility and become spontaneously obese [82, 83]. Importantly, Pearce et. al., 
have identified multiple rare variants in the Ksr2 gene that disrupt signaling through the 
ERK1/2 pathway, causing severe early-onset obesity in patients [84]. Carriers of Ksr2 
mutations present with childhood hyperphagia, low heart rate, reduced basal metabolic 
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rate, and severe insulin resistance [84]. Overall, both KSRs are physiologically important 
for the ERK1/2 signal transmission [1, 69, 73, 75, 77].  
  
4.2 MAPK/ERK kinase 1 partner (MP1)/p14/p18 complex 
An additional scaffold module that was shown to regulate ERK1/2 activity is the 
MP1/p14/p18 protein complex [85, 86]. A small 14 kDa protein, MP1, was identified as a 
MEK scaffold in a yeast two hybrid screen. MP1 forms stable heterodimers with an 
adaptor protein p14, which is responsible for the localization of MEK1 to the late 
endosomal compartment. On endosomes, the MP1-p14 complex promotes the assembly 
and interaction with signaling molecules MEK1 and ERK1 [87, 88]. In vitro studies by 
Schaeffer et al. demonstrated that MP1 stimulates phosphorylation of MEK1 by RAF and 
the interaction of MEK1-ERK1 [1, 85, 86].  
The endosomal localization of the MP1-p14 complex is crucial for the complete 
ERK1 activation in response to EGF stimulation [85, 86, 88]. Depletion of p14 results in 
mislocalization of MP1 from late endosomes to the cytoplasm and decreased 
phosphorylation of ERK1 [85, 89]. The MP1-p14 scaffolding complex is anchored on the 
endosomal membrane by the small polypeptide p18 [90]. p18 is recruited to late 
endosomal lipid rafts by N-terminal myristoylation and palmitoylation and anchors the 
scaffold MP1-p14 heterodimer to the cytoplasmic surface of late endosomes [90]. The 
MP1/p14/p18 scaffold complex is also known as the LAMTOR1-2-3 complex for its 
function in the mTORC1 mediated sensing of amino acids [91-93].  
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Properties of the MP1-p14-p18 complex support the notion that scaffold proteins 
provide means for the spatial organization of signaling cascades and that endosomes 
serve as a meeting ground for signaling components [94, 95]. 
 
4.3 IQ motif-containing GTPase activating protein 1 (IQGAP1) 
Another notable scaffold protein, IQGAP1, is the best-characterized member of the 
IQGAP family that includes three paralogs in humans, IQGAP1, IQGAP2, and IQGAP3. 
[96]. IQGAP1 is a large (190 kDa) ubiquitously expressed protein that regulates many 
signaling pathways, including ERK1/2 [1, 97].  
As a scaffolding protein, IQGAP1 mediates numerous protein-protein interactions via 
its multiple domains. Its IQ domain is similar to the catalytic domain of Ras-GTPase-
activating proteins (GAPs). IQGAP’s domain, including calponin-homology domain 
(CHD), WW domain, a GTPase-activating protein-related (GRD) domain, and a RasGAP 
C-terminal domain, mediate binding of partners such as Cdc42 and Rac1, actin, 
calmodulin, E-cadherin, β-catenin, S100B, nectin, CLIP-170, mTOR and Akt, and form 
multiprotein complexes [97-106].  
IQGAP1 interacts with B-RAF, MEK1/2, and ERK1/2, recruits them to the actin 
filaments, and positively regulates ERK1/2 signals [107]. Alterations in the levels of 
IQGAP1 expressed in cells abrogated EGF-dependent activation of MEK1/2 and ERK2, 
indicating its crucial role for efficient ERK1/2 signaling propagation [59].  
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4.4 Suppressor of Ras-8 (Sur-8 or Shoc2)  
Sur-8/Soc2, suppressor of clear were isolated in C. elegans genetic screens [108]. 
Several following studies suggested that Sur-8/Shoc2 enhances ERK1/2 activity by 
forming a ternary complex with Ras and RAF-1 kinase in response to growth factors 
stimuli [109-111] and showed that Shoc2 can interact with several Ras isoforms [109, 
110, 112, 113]. Mammalian Shoc2 is a remarkably evolutionarily well-conserved protein 
[111]. All known Shoc2 orthologues are comprised of two major domains: the short, 
unstructured N-terminal domain followed by the long stretch of leucine-rich repeats 
(LRRs) [111]. Similar to other proteins that contain tandem arrays of multiple LRRs, 
Shoc2 likely forms a horseshoe-shaped solenoid structure which generates a platform 
holding several binding partners with only a few being identified. The involvement of 
each known interacting partner (i.e. PP1c, SCRIB, Erbin, HUWE1, PSMC5) in the 
regulation of the Shoc2 function, assembly of the scaffolding complex, and/or subsequent 
control over the ERK1/2 signaling is discussed separately.  
The biological significance of Shoc2 was explored in several studies [114-120]. 
The total knockout of Shoc2 in mice led to an early embryonic lethality [121]. This study 
made a surprising conclusion: Shoc2 is able to regulate atrioventricular canal 
development in an ERK-independent manner [121]. Yet a number of other groups 
demonstrated that this non-enzymatic protein enhances ERK1/2 activation in response to 
EGFR and fibroblast growth factor receptor (FGFR) activation [108, 117, 122, 123]. 
Although our current understanding of biological processes and targets regulated via 
signals transmitted through the complex is incomplete, several attempts have been made 
to delineate the physiological role of Shoc2. Along with the potential role of Shoc2 in 
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differentiation and proliferation of neuronal progenitor cells, Shoc2’s role was examined 
in tumorigenesis of cells such as pancreatic, colon, breast, and non-small cell lung 
carcinomas, melanoma and hepatoma cells [112, 114, 115, 119, 124]. Activity of ERK1/2 
transduced by Shoc2 was shown to contribute to the malignant properties of various 
tumor cells via regulating contact inhibition, anchorage-independent proliferation and 
orientation of the microtubule-organizing center of these cells. The Galperin lab showed 
that Shoc2 modulates ERK1/2 signals for cell motility and attachment, in part, through 
regulating expression of the protein of extracellular matrix lectin galactoside-binding 
soluble 3-binding protein (LGALS3BP) [118].  
 
Efforts to understand the mechanisms by which Shoc2 controls ERK1/2 activity 
revealed the intricate machinery that governs the ability of Shoc2-transduced Ras-RAF 
signals. Catalytic subunit of protein phosphatase 1c (PP1c) is one of the three catalytic 
subunits of serine/threonine specific protein phosphatase 1 (PP1) [125, 126]. PP1c, 
known for its capacity to cooperate with various regulatory subunits, forms a holoenzyme 
with Shoc2 [110]. The Shoc2-PP1 holoenzyme is targeted to stimulate RAF-1 kinase 
activity by dephosphorylating the S259 inhibitory site. It was hypothesized that M-
Ras/Shoc2/PP1c complexes then activate RAF-1 recruited by other Ras proteins or Ras 
family GTPases [110].  
 
 Scribbled homolog (SCRIB) is a member of the evolutionarily conserved LAP 
(LRR and PDZ) protein family and a known regulator of the ERK1/2 pathway [127]. 
SCRIB is involved in regulating cell polarity and has properties of a tumor suppressor 
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[127-130]. In Drosophila, loss of SCRIB results in neoplastic outgrowth, and SCRIB 
cooperates with activated Ras to promote invasion and metastasis [131]. Young et al. 
showed that SCRIB antagonizes Shoc2-mediated RAF-1 (S259) dephosphorylation 
through a mechanism involving competition for PP1c molecules within the same 
scaffolding complex [119]. Competition of Shoc2 and SCRIB for PP1c is part of the 
intricate mechanisms that controls the frequency and amplitude of Shoc2-transduced 
ERK1/2 activity and affects cell polarity and tumorigenic growth [119].  
 Erbb2 Interacting Protein (Erbin), also known as ERBB2IP, is another member 
of the LAP protein family [132]. Erbin interacts, via its PDZ domain, specifically with 
Erbb2, but not with Erbb3, Erbb4, or EGFR [133, 134]. Similar to SCRIB, Erbin is a 
negative regulator of the Ras-RAF-ERK1/2 signaling pathway [135]. In keratinocytes 
and cardiomyocytes, Erbin dampens ERK1/2 activity by disrupting the interaction of 
Ras-RAF-1 that is mediated by Shoc2 [136-139]. The depletion of Erbin increases the 
interaction of Shoc2 with Ras and RAF, and ERK1/2 activation. Both SCRIB and Erbin 
appear to provide an essential mechanism to control signaling strength of Shoc2-ERK1/2 
activation in a spatio-temporal manner [109, 119, 139]. 
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Proteins of ubiquitin machinery  
 Shoc2-ERK1/2 signals are fine-tuned through Shoc2 partnering with proteins of 
the ubiquitin machinery: the HECT-domain E3 ubiquitin ligase HUWE1 and the AAA+ 
ATPase PSMC5 [116, 120].  
  HECT, UBS and WWE domain containing 1 (HUWE1)  
 The HECT-domain E3 ubiquitin ligase HUWE1 (also called ARF-BP or MULE) 
is an interacting partner in the Shoc2-Ras-RAF-1 scaffold complex [120]. HUWE1 has 
been implicated in the regulation of cell proliferation, apoptosis, neural differentiation, 
and the DNA damage response [140-142]. It is mainly expressed in heart, placenta, and 
brain. Increased HUWE1 levels have been found in cancers (i.e. lung, breast, and 
colorectal carcinomas) and HUWE1-mediated ubiquitination has been linked to cancer 
via its ability to target substrates such as p53 and c-Myc for degradation [143-148]. In the 
Shoc2 scaffolding module, HUWE1 ubiquitinates Shoc2 which is a prerequisite for the 
subsequent ubiquitination of the RAF-1 kinase by HUWE1. HUWE1-mediated 
ubiquitination regulates the stability of both Shoc2 and RAF-1. Importantly, abrogated 
Shoc2 ubiquitination leads to impaired RAF-1 ubiquitination, increased ERK1/2 
phosphorylation, and higher rates of cell proliferation [120]. HUWE1 acts as the ERK1/2 
signal-tuning component in the scaffold complex, thereby controlling the intensity of 
ERK1/2 signaling flow through Ras and RAF-1. Hence, HUWE1 provides a negative 
feedback mechanism that modifies the amplitude of Shoc2-mediated ERK1/2 signaling 
through allosteric post-translational modifications [120]. 
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ATPase associated with diverse cellular activities (AAA+) ATPase 5, 
(PSMC5)  
 An additional protein of the ubiquitin machinery regulating Shoc2-mediated 
ERK1/2 signaling is the AAA+ ATPase PSMC5 [149]. PSMC5 (rpt6 or Sug1), widely 
known for its essential role in the 19S proteasome [150], also functions as an 
unfoldase/remodeler of AAA+ Proteins Independent of 20S (APIS) complexes [116, 
151]. In the Shoc2 assembly, PSMC5 has a unique role that does not involve a control 
over stability of Shoc2 or its known partners. Experiments using ATPase activity 
deficient mutants of PSMC5 demonstrated that PSMC5 is required for the remodeling of 
the Shoc2 complex in a spatially defined manner. PSMC5 targets Shoc2 complexes to 
endosomes for the Shoc2 complex remodeling. While HUWE1-mediated ubiquitination 
of Shoc2 and RAF-1 allows for the dynamic range of RAF-1 activity to be fine-tuned, 
PSMC5 controls the ability of HUWE1 to modify the non-catalytic scaffold Shoc2, 
thereby actively modulating the assembly of molecules in the complex [116, 120]. 
 
5. Shoc2 mutations in RASopathy patients 
Importantly, Shoc2 is the only scaffold protein for which mutations have been 
identified in RASopathy patients. In 2009, Cordeddu and coworkers reported that the 
c.4A>G (p.S2G) missense mutation in the Shoc2 gene causes a Noonan-like syndrome 
with loose anagen hair (NSLH)(OMIM 607721) [152]. The c.4A>G (p.S2G) substitution 
subsequently leads to a protein with the abnormally added myristate fatty acids that is 
aberrantly targeted to the plasma membrane. The first group of patients carrying the 
c.4A>G mutation were reported to have an unusual combination of features where 
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reduced growth associated with growth hormone deficiency, cognitive deficits, 
distinctive hyperactive behavior, and a unique hair anomaly [152]. These findings were 
then expanded from distinctive craniofacial dysmorphisms and a wide spectrum of 
congenital heart defects to variable neurocognitive impairments, brain anomalies, 
epilepsy, severe hydrops fetalis, and even Moyamoya syndrome [152-157]. A different 
substitution (c.519G>A; p.M173I) in shoc2 was later recently reported by Hannig et al. in 
patients with the mild NSLH [158]. Molecular studies by the Galperin lab revealed that 
an impaired ability of the Shoc2 M173I mutant to interact with protein phosphatase 1c 
(PP1c) which activates Shoc2 bound RAF-1 kinase [110, 158]. These clinical and 
molecular studies further emphasized the importance of the cellular localization of Shoc2 
and the proper assembly of the Shoc2 scaffold complex. Interestingly, patients with de 
novo missense mutations in PP1c were reported to closely resemble Noonan syndrome 
with loose anagen hair [159]. Patients had relative or absolute macrocephaly, low-set and 
posteriorly positioned ears, developmental delay, slow growing and/or sparse hair and/or 
an unruly hair texture, which are all overlapping phenotypes in Shoc2 patients. Therefore, 
in order to understand the pathology of NSLH it is necessary to decipher the mechanism 
by which the Shoc2 scaffold regulates ERK1/2 pathway activity as well as the functions 
of each Shoc2-interacting partners in the module.   
 
6. Scope of the dissertation study 
The studies presented in this dissertation are focused on understanding specific 
biological signals transmitted through the scaffold module Shoc2 as well as deciphering 
the molecular mechanisms regulating the Shoc2 signaling module. Chapter 3 summarizes 
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studies that examine the physiological role of Shoc2-transmitted ERK1/2 signals using a 
heritable zebrafish vertebrate model. I found that Shoc2 is essential for early 
development and its loss is detrimental to a normal hematopoiesis and development of 
the neural crest in zebrafish. Chapter 4 characterizes the novel molecular interaction of 
Shoc2 with its previously unknown binding protein Valosin-containing protein (VCP). I 
found that VCP is critical for the proper remodeling of the Shoc2 signaling complex and 
a fine-tuning of the ERK1/2 signals transmitted via the Shoc2-Ras-RAF-1 complex. I 
also found that alterations in the ubiquitination of Shoc2 and ERK1/2 activity are novel 
aspects in the pathology of Inclusion Body Myopathy with Paget’s disease of bone and 
Frontotemporal Dementia (IBMPFD).  
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CHAPTER 2 
 
 
Material and Methods 
 
 
 
A. Materials and Methods used in CHAPTER 3 
 
1. Zebrafish strains and maintenance  
All zebrafish (Danio rerio) strains (AB and Sanger AB Tubingen) were bred, raised, 
and maintained in accordance with established animal care protocols for zebrafish 
husbandry [160]. Adult fish, embryos, and larvae were housed at 28 °C, on a 14 h light: 10 
h dark cycle. Embryos were staged as previously described [161]. All animal procedures 
were carried out in accordance with guidelines established by the University of Kentucky 
Institutional Animal Care and Use Committee. 
 
2. Cloning of zebrafish Shoc2 cDNA 
Total RNA of 120 hours post fertilization (hpf) zebrafish was extracted with 
RNAzol reagent (Bio-Rad) and reverse-transcribed using iScript RT Supermix according 
to the manufacturer’s recommendations (Bio-Rad). Primers used to amplify Shoc2 are:  
Forward primer: 5-ATGTGCCATTGGACTGCGG-3’  
Reverse primer: 5’-GTCCAAGGTAAAGGCCACCG-3’  
Primers used to amplify Shoc2 insensitive to ATG morpholino are: 
Forward primer: 5’- ATGTCATCGACTCTGGGCAAAGATAAAGAC-3’  
Reverse primer: 5’-TCAGACCATGGCGCGGTA-3’  
PCR products were cloned into TA vector and validated by Sanger sequencing. 
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3. Whole-mount in situ hybridization 
Sense and antisense shoc2 RNA probes were prepared by in vitro transcription of 
linearized plasmids containing a portion of the coding sequence of Shoc2, using T7 
polymerase and digoxigenin (DIG) labeling mix (Roche).  
A standard protocol used to perform whole-mount in situ hybridization is as follows:  
1. Embryos were fixed overnight at 4 °C in freshly prepared 4% paraformaldehyde in PBS 
(pH 7.0). Samples were dehydrated with 4 changes of 100 % methanol and stored at -20 °C 
for a minimum of 24 h.  
2. Tissues were gradually rehydrated from methanol into PBST (PBS, 0.1% Tween-20) 
and permeabilized in proteinase K (20 μg/ml in PBST). Frequent observations were made 
under the microscope for signs of digestion. Enzyme reaction was stopped by washing 
samples with PBST, followed by replacement with hybridization buffer (50% Formamide, 
5X Saline Sodium Citrate buffer (SSC), 5 mg/ml yeast RNA, 50 μg/ml heparin sulfate, 0.1% 
Tween-20) for a minimum of 2 h at 60 °C. 
3. Riboprobes (shoc2 sense and anti-sense) were hybridized to the tissue overnight at 60 °C 
at a final concentration of 2 ng/μl in hybridization buffer. 
4. Samples were washed with a gradual series of SSC at 60 °C and 70 °C, and a graded 
PMST series at room temperature, before blocking for a minimum of 2 h at 4 °C in PBST 
containing 2% BSA and 2% sheep serum.  
5. Samples were incubated overnight at 4 °C with an anti-DIG-AP antibody (Roche) diluted 
1:1500 in blocking buffer, and equilibrated in NTMT buffer (0.1 M Tris pH 9.5, 0.05 M 
MgCl2, 0.1 M NaCl, 0.1% Tween-20) before coloration with 4-Nitro blue tetrazolium 
(NBT; Roche) and 5-bromo-4-chloro-3-indolyl-phosphate, 4-toluidine salt (BCIP; Roche) 
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in NTMT. Frequent observation was made under the microscope and the coloration 
reaction was stopped by stop solution (PBS pH 5.5, 1 mM EDTA). 
 
4. Morpholino (MO) and mRNA injection 
All MOs were obtained from Gene Tools, LLC. MO (5.2 ng) were injected into 1-
2 cell stage zebrafish embryos. A standard control MO and two non-overlapping shoc2-
specific MO used is the experiments are as following:  
standard control MO: 5’- CCTCTTACCTCAGTTACAATTTATA-3’ 
shoc2 MO1: 5’- TACTGCTCATGGCGAAAGCCCCGCA-3’  
shoc2 MO2: 5’- TCCAATGGCACATGGGACCCTCAGT-3’. 
Both shoc2 MO1 and MO2 generated similar phenotypes. All data presented in this study 
were from embryos injected with shoc2 MO1.  
The human shoc2 cDNA was amplified using primers introducing silent 
mutations rendering RNA insensitive to shoc2-MO and then cloned into the pGEM-T-
easy vector (Promega). Primer sequences used to generate human shoc2 cDNA are as 
following: 
Forward primer: 5’-ATGAGTAGTAGTTTAGGAAAAG-3’ 
Reverse primer: 5’-TCAGACCATGGCACGATATGG-3’ 
The capped mRNAs were synthesized with the mMessage mMACHINE transcription kit 
(Life Technologies) according to the manufacturer’s recommendations. For mRNA 
rescue experiments, 100 pg/embryo of WT shoc2 mRNA was co-injected with 5.2 ng of 
shoc2 MO1 into 1-2 cell stage zebrafish embryos. 
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5. shoc2 CRISPR sgRNA target design  
Shoc2 CRISPR target sites were identified and the corresponding sgRNA oligos 
were designed using the ZiFiT online software package (www.zifit.partners.org/ZiFiT). 
To note, it is helpful to choose multiple sites and co-target them by co-injecting more 
than one gRNA.  
How to use ZiFiT software: 
1. Navigate to the ZiFiT website and follow links to the “CRISPR/Cas9 nucleases” site. 
2. Copy and paste the target region from the target gene’s genomic sequence file into the 
text box.   
3. Select “T7 promoter” which will ensure that the CRISPR target begins with “GG”, the 
preferred starting bases for T7 RNA polymerase. 
4. Specify the length of target site as 20 bp.  
5. Select “Zebrafish” for species.  
6. Click “Identify target sites”. 
7. Click “Identify potential off target sites”. Eliminate candidate targets that have off-
target sites containing only 1 bp or 2 bp mismatches compared to the target.  
8. Choose a few non-overlapping targets with low predicted off-targeting on the mRNA 
sequence file.  
9. Eliminate candidate CRISPR target sites with an obvious stretches of self-
complementary sequence that might cause hairpin formation.  
10. Prioritize candidate CRISPR targets containing restriction enzyme (RE) sites as RE 
analysis provides an alternative method to screen for genotypes.  
11. Choose the most preferred target site(s), and annotate onto genomic sequences. 
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12. Generate high resolution melting analysis (HRMA) primers using genomic sequence 
and check that the amplicon sequence predicts a smooth melting curve using uMelt 
online software.  
 
6. Plasmid-based CRISPR sgRNA and Cas9 mRNA synthesis and injection 
Oligonucleotides corresponding to the shoc2-specific sgRNA CRISPR/Cas9 
target site were purchased (standard primers with salt-free clean up). If using a different 
design software, the insert-oligos can be designed using the target site. To generate 
“insert-oligo 1 (forward)”, simply add “TA” 5’ to the target sequence. To generate 
“insert-oligo 2 (reverse)”, delete the GG at the beginning of the target sequence, then 
reverse complement the target sequence, and finally add “AAAC” to 5’ of this sequence. 
When mixed together, the insert-oligos will create a double-stranded targeting sequence 
flanked by 4 bp single-stranded overhangs, compatible with the overhangs generated by 
Bsa1 digestion of pDR274. The sequences for targeting shoc2 exon 2 and exon 3 were as 
follow: 
Target site (exon 2) sequence: GGTGGGATGCCTGTCAGGAT 
Oligo 1: TAGGTGGGATGCCTGTCAGGAT 
Oligo 2: AAACATCCTGACAGGCATCCCA 
 Target site (exon 3) sequence: GGATGTAGCCCACAACCAGT 
  Oligo 1: TAGGATGTAGCCCACAACCAGT 
  Oligo 2: AAACACTGGTTGTGGGCTACAT 
1. pDR274 (AddGene; plasmid #42250) was linearized with Bsa1-HF (NEB #R3535S) at 
37 °C for at least 3 h. 
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     300~1000 ng of pDR274 
               1 µl Bsa1-HF 
   1 µl CutSmart Buffer 
      Up to 10 µl Sterile water 
2. Linearized vector was purified using PCR clean up kit and ran on a 1% agarose gel. 
Single band at 2.1 kb was observed. 
3. Oligonucleotide annealing:   
a. Mixed an equal amount of oligonucleotides of forward and reverse strands;  
10 µl of NEB buffer #4 
10 µl of 100 µM forward  
10 µl of 100 µM reverse 
70 µl of water    
b. Used PCR machine for annealing 
              5 min 97 °C 
               2 min 50 °C 
               2 min room temperature 
               5 min 4 °C 
4. Ligation:  
           a. Mixed 3 µl of annealed oligos 
digested vector       300-1000 ng 
ligation buffer                     5 µl 
sterile water                       30 µl 
Total                                  48 µl 
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b. Incubated at 50 °C for 2 min 
c. Incubated at room temperature for 5 min 
d. Incubated on ice for 5 min 
e. Added 2 µl of T4 DNA ligase and incubated overnight at 16 °C 
5. Transformation was performed using 5 µl of the ligation product. 
6. 5 bacterial colonies were chosen and cultured in 5 ml of LB media (+ Kanamycin) 
overnight. Plasmid DNA was purified using Plasmid MiniprepTM –Classic kit (Zymo 
Research) and validated by Sanger sequencing using M13F primer (5’-
TGTAAAACGACGGCCAGT-3’). 
7. Plasmids were digested using DraI (NEB #R0129S) at 37 °C for at least 3 h. 
Plasmid        5 µg 
DraI         4 µl 
CutSmart NEB buffer      5 µl 
            Sterile water up to     50 µl 
8. Digested plasmids were analyzed on a 1% agarose gel. The 286 bp DNA band was gel 
extracted and used for shoc2 sgRNA synthesis. 
9. To generate Cas9 mRNA: 
1) Purified high quality pCS-nCas9n (Addgene) plasmid DNA (Midiprep). 
2) Linearized pCS-nCas9n using NotI-HF (NEB, #R3189S) at 37 ºC for at  
least 3 h. 
             Plasmid    20 µg 
             NotI-HF   10 µl 
             CutSmart buffer  10 µl 
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             Sterile water to            100 µl 
3) Purified linearized plasmid using PCR cleanup kit (Qiagen) and resolve the  
digested on a 1% agarose gel for diagnosis.  
4) sgRNA and Cas9 mRNA were synthesized using the mMESSAGE  
mMACHINE SP6 Transcription Kit (Life Technologies). To confirm the quality  
of sgRNA and Cas9 mRNA, each RNA was mixed with formamide, heated at 72  
°C for 5 min and resolved on a 1% (w/v) agarose gel.  
 
7. Microinjection of shoc2 sgRNA and Cas9 mRNA 
The following injection mixture was prepared and 0.2 mm-diameter droplet was 
injected into each 1-2 cell stage wild-type embryos:  
200 pg/embryo of shoc2 sgRNA               x µl 
300 pg/embryo of Cas9 mRNA                 x µl 
Danieu’s buffer (20x)                                1 µl 
DesRed (10x)                                             2 µl 
Sterile water (DNAase/RNAse free) to    20 µl  
 
8. High Resolution Melting Analysis (HRMA) 
When designing sgRNA, it is important to ensure that the target sites have good 
primers flanking the CRISPR target site for HRMA and sequencing. The Following 
primer design was recommended in the manual of “LightCycler 480 Real-Time PCR 
System” that was utilized in our experiments.  
To choose the best HRMA primers: 
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1. Choose primer pair that produces amplicons no longer than 150 bp (75 bp < product 
length < 150 bp works the best). Short amplicons are more likely to show the effects of 
small sequence variations. 
2. Design PCR primers that have annealing temperatures around 60 ⁰C. 
3. Avoid primers that are likely to form primer dimers or nonspecific products. 
4. BLAST the primer sequences to ensure they are specific for the target species and 
gene. 
5. Order the primers at 10 nM scale with salt-free clean up.  
6. Check the specificity of the PCR product on agarose gel. Check if the reaction contains 
primer dimers or nonspecific products as these are not suitable for HRMA.  
7. Reorder the primers at 200 nM in HPLC purification grade. 
To isolate genomic DNA from un-injected or sgRNA/Cas9 injected individual 
embryos, 24 hpf de-chorionated embryos were placed into individual wells of a 96-well 
plate containing 20 µl of 1X ThermoPol Buffer (New England Biolabs). The plate was 
placed in a PCR cycler at 95 °C for 10 min, after which 5 µl of 10 mg/ml Proteinase K 
(Sigma) was added to each well and the plate was incubated at 55 °C for 1 h and 95 °C 
for 10 min. HRMA was performed using a LightCycler 96 RealTime PCR System 
(Roche) and LightCycler 480 High Resolution Melting Master (Roche) according to the 
manufacturer's instructions. At least 3 un-injected embryos were included as a control 
along with 3 no-template control.  
  2x Master mix                                    10  µl 
  Forward primer (10 µM)                   0.2 µl 
  Reverse primer (10 µM)                    0.2 µl 
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  MgCl2 stock solution (25 mM)          1.2 µl 
  Water (PCR grade)                            6.4 µl 
  Genomic DNA       2 µl 
Primer sequences (HPLC grade): 
shoc2Δ22 5’-CCATCAAGGAGCTGACCCAG-3’  
  5’-TCTGACCAGCCTACCTGACT-3’,  
shoc2Δ14 5’-AGCGACTCTGTTGTCTTGTGTTA-3’  
  5’- AGGTTGGTGATCTGAGTGCAA-3’  
 
9. DNA extraction and genotyping  
Genomic DNAs were extracted from individual embryos or adult tail clips. 
Briefly, 20 µl of the ThermoPol Buffer (New England Biolabs) was added to the samples 
and boiled for 5 min and digested with Proteinase K (10 mg/ml) for 2 h at 55 °C. 
Proteinase K (10 mg/ml) was then inactivated by boiling for 10 min after digestion. PCR 
was carried out in a 25 µl reaction solution containing: 1 µl of 10 mM dNTP, 1 µl of 10 
mM forward and reverse primer, 2.5 µl of 1x ThermoPol buffer (New England Biolabs), 
and 0.5 units of TaqPolymerase (New England Biolabs).  
Primers (salt-free grade): 
shoc2Δ22 5’-CCATCAAGGAGCTGACCCAG-3’  
  5’-TCTGACCAGCCTACCTGACT-3’,  
shoc2Δ14 5’-AGCGACTCTGTTGTCTTGTGTTA-3’  
  5’- AGGTTGGTGATCTGAGTGCAA-3’  
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10. Real-time quantitative RT-PCR  
Total RNA was isolated from the pool of five embryos at 6 dpf using 
PureZOL/Aurum Total RNA Isolation Kit (Bio-Rad) according to the manufacturer's 
recommendations. Aliquots containing equal amounts of RNA were subjected to RT-PCR 
analysis. qPCR was performed using SoAdvanced SYBR green Supermix and a Bio-Rad 
CFX detection system (Bio-Rad). Relative amounts of RNAs were calculated using the 
comparative CT method [162]. Sequence-specific primer sets are presented in Table. 1. The 
values for the samples were normalized against those for the reference gene, and the results 
are presented as the fold change in the amount of mRNA recovered from WT and mutant 
embryo. The data represent the means ± SEM from three independent experiments. 
 
11. Western Blot Analysis using zebrafish embryos 
Protein lysates were extracted from pools of 30-60 de-chorionated and de-yolked 
embryos at 12, 24, 48, and 72 hpf. Protein concentrations were measured using the Bio-
Rad protein assay dye reagent (Bio-Rad). 35 μg of total protein per lysate was diluted with 
Laemmli buffer and 2.5% β-mercaptoethanol, boiled for 5 min, and then separated by SDS-
PAGE on 10% polyacrylamide gels. Proteins were transferred to nitrocellulose membranes 
and visualized using ChemiDoc analysis system (Bio-Rad). Several exposures were 
analyzed to determine the linear range of the chemiluminescence signals. Quantification 
was performed using the densitometry analysis mode of Image Lab software (Bio-Rad). 
Antibodies against the following proteins were used: Shoc2 (Genetex), total ERK1/2 
(tERK1/2), phosphorylated ERK1/2 and β-actin (pERK1/2, Santa Cruz Biotechnology).  
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12. Staining methods for zebrafish embryos 
Whole embryo staining for erythropoietic cells was performed using o-dianisidine 
histochemistry according to previously described methods [163]. PTU (1-phenyl-2-
thioure) treated de-chorionated embryos were stained for 30 min in the dark in o-
dianisidine (0.6 mg/ml), 0.01 M sodium acetate, 0.65% H202, and 40% (vol/vol) ethanol. 
After staining, embryos were washed with PBS-T (Phosphate buffer saline with 0.1% 
Tween-20) and then post-fixed in 4% paraformaldehyde (PFA) overnight in 4 °C. Sudan 
Black B staining was performed to detect neutrophils and macrophages. Whole embryos 
were fixed with 4% PFA for 2 h at room temperature, rinsed in PBS, and incubated with 
Sudan Black B solution (2 mg/ml Sudan Black B dissolved in 70% ethanol) in the dark 
for 30 min. Stained embryos were then washed with 70% ethanol and stored in 90% 
glycerol for imaging. Histochemical staining for the myeloperoxidase activity of whole 
zebrafish embryos was performed according to the manufacturer’s instructions (Sigma-
Aldrich).  
For Alcian blue staining, zebrafish larvae were washed with sterile water and 
fixed in 4% paraformaldehyde for 2 h at room temperature and stained according to 
Kimmel et al., 1998 [164]. Calcified structures were examined by acid-free Alizarin Red 
S staining. Embryos were fixed in 4% PFA for 2 h and stained in a 0.05% Alizarin Red S 
solution in water for 30 min in the dark on low agitation, rinsed in a 50% glycerol, 0.1% 
KOH solution to remove excessive staining, and kept at 4 C in the same solution for 
imaging.  
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13. Isolation of hematopoietic cells from zebrafish embryos 
Embryos of homozygous gata1-DsRed transgenic fish were collected and treated  
with PTU after 24 hpf. 
1. Embryos were collected at 72 hpf and sedated using tricaine.  
2. Embryos were incubated with 0.05% Trypsin-EDTA solution and dissociated the tissue  
using 20 G syringe.  
3. Cells were filtered through 40 µm cell strainer (DNAse/RNAse free) to obtain a single 
cell suspension and spun down at 4 °C for 10 min at 3500 rpm.  
4. Cell pellet was re-suspended in PBS (+ 2mM EDTA) and processed with a flow 
cytometer.    
 
14. Cytology of peripheral blood 
For cytological analyses, blood cells collected from zebrafish larvae were 
transferred onto glass slides by cytospin (2500 rpm, 3 min) and stained with May-
Grünwald Giemsa stain (Sigma-Aldrich) following the manufacturer’s instructions.  
1. Diluted Giemsa Stain (Cat# GS500) 1:20 with deionized water.  
2. Placed slides in May-Grünwald Stain (Cat# MG500) for 5 minutes.  
3. Placed slides in working phosphate buffer (0.1 M, pH 7.2) for 1.5 minutes.  
4. Placed slides in diluted Giemsa solution from step 1 for 15-20 minutes.  
5. Rinsed slides briefly in deionized water.  
6. Air dried and imaged. 
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15. Statistical analyses  
Results are expressed as means ± SEM. The statistical significance of the 
differences between groups was determined using either Student's t-test or one-way 
ANOVA (followed by the Tukey's test). P < 0.05 was considered statistically significant. 
All statistical analyses were carried out using SigmaStat 13.0 (Systat Software Inc). 
 
16. Photography and image analysis 
Images of the phenotypes of embryos or larvae and images of whole-mount in situ 
hybridization were captured with a Nikon DS-Ri2 digital camera mounted on a dissecting 
microscope (Nikon SMZ18) or an inverted microscope (Nikon Eclipse Ti-U; Nikon 
Instruments). NIS-Elements software (Nikon) was used to calculate the body lengths, eye 
size and areas of Alcian blue and Alizarin Red S -positive signals. Images of mpx 
staining were photographed with a Leica DFC450 digital camera and May-Grünwald 
Giemsa staining were imaged with Leica DFC 7000 T mounted on a dissecting 
microscope (Leica S9D). All images were compiled in Adobe Photoshop CS6 Portable 
(Adobe Systems Incorporated) and resized. 
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B. Materials and methods used in CHAPTER 4 
 
1. Antibodies and other reagents 
EGF was obtained from BD Biosciences. Antibodies against the following proteins 
were used: RAF-1, glutathione S-transferase (GST), GFP, HA, phosphorylated ERK1/2 
(pERK1/2), M-Ras, and GAPDH (Santa Cruz Biotechnology); Shoc2 (Proteintech); EEA1 
and phosphorylated RAF-1 (pRAF-1, Cell signaling); Rab5 (BD Bioscience); RFP and 
Na+/K+-ATPase (Thermo Scientific), VCP (BioLegend), HUWE1 (Bethyl); ubiquitin 
(Covance); and CB-5083 was kindly provided by Cleave Bioscience. 
 
2. Yeast two-hybrid screening assays 
Full-length human Shoc2 was cloned into the lexA vector pB27 as an N-LexA-
Shoc2-C fusion and screened against a human embryo ventricle and heart prey cDNA 
library. Yeast two-hybrid screens were performed by Hybrigenics SA.  
 
3. DNA constructs and cell cultures  
VCP-GFP constructs (WT, R155H, E305Q/E578Q) were purchased from Addgene 
(plasmid #23971, 23972, 23974). Shoc2-GST, Shoc2(LRR12-14)-GST, Shoc2-tRFP 
truncated mutants, Shoc2(Δ21-C)-tRFP, Shoc2-YFP, Shoc2(7KR)-YFP, PSMC5-GST, 
MRas-YFP, MRas-HA, YFP-RAF-1, HA-HECT and HA-Ub constructs were described 
previously [120]. Shoc2(Δ12-14)-GST construct was generated as described previously 
[120]. All constructs were verified by dideoxynucleotide sequencing. HEK 293FT cells 
(Invitrogen), Cos1 (ATCC), and stable cell lines (SR, SY, S2G, Δ21-C) (derivative of Cos1 
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cells) were cultured in Dublecco Modified Eagle’s Medium (DMEM, Sigma) containing 
10% fetal bovine serum (FBS, Biowest) and Penicillin-Streptomycin solution (Hyclone). 
Primary fibroblasts (GM22757, GM23284, GM22600, GM22085) were obtained from 
Coriell Institute and were maintained in FibroLife S2 Cell Culture Medium containing 
FibroLife S2 LifeFactors (Lifeline Cell Technology).  
 
4. Transfection 
DNA transfections were performed using PEI (Neo Transduction Laboratories) 
reagent. Briefly, 200 µl of DMEM, 2 µg of DNA construct, and 7 µl of PEI reagent were 
mixed together in a 1.5 ml Eppendorf tube and incubated at room temperature for 20 min. 
The ratio of DNA:PEI was always kept as 1:3.5.  
 
5. siRNA transfections 
To silence protein expression, small interfering RNA (siRNA) transfections were 
performed at 24 to 36 h intervals according to the manufacturer’s recommendations, using 
DharmaFECT reagent 2 (Thermo Fisher Scientific/Dharmacon). The siRNA sequence used 
to target the HUWE1 and Shoc2 transcripts were described previously [120]. The following 
protocol was implemented: 
1. Plate cells a day before transfection to ensure that the cells are actively dividing and 
reach 70% confluence cell density at the time of transfection.   
2. Prepare a 20 µM siRNA stock solution using siRNA buffer. 
3. In separate tubes, prepare the following:  
Tube 1 – Add 2.5 µl of siRNA stock to 100 µl of serum-free medium.  
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Tube 2 – Add 7 µl of DharmaFECT reagent 2 to 100 µl of serum-free  
medium. 
4. Mix the contents of each tube gently by pipetting carefully up and down and incubate 
for 5 min at room temperature. 
5. Add contents of Tube 1 to Tube 2. Mix by pipetting carefully up and down and incubate 
for 20 min at room temperature. 
6. Add the mixture onto the cells and incubate for 24-48 h. 
   
6. Sucrose gradient subcellular fractionation 
Sucrose gradient subcellular fractionation was performed as described previously 
[116, 165]. Briefly, cells were cultured on 15-cm2 dishes, washed, and collected using a 
rubber policeman into cold PBS. The cells were then pelleted, resuspended in 
homogenization buffer (250 mM sucrose, 3 mM imidazole (pH 7.4), EDTA 1 mM, protease 
and phosphatase inhibitors, and 0.03 mM cycloheximide), and homogenized using 22G 
needle. Homogenization was carried out until ∼90% of cells were broken without major 
breakage of the nucleus, as carefully monitored under the microscope. Samples were then 
centrifuged for 10 min at 2000 g at 4°C and the resulting supernatant was designated as the 
post nuclear supernatant (PNS). The PNS was adjusted to 40.6% sucrose concentration 
using 62% sucrose (2.351 M sucrose, 3 mM imidazole (pH 7.4), 1 mM EDTA, sterile water) 
and then overlaid with 1.5 volumes of 35% sucrose (1.177 M sucrose, 3 mM imidazole 
(pH 7.4), 1 mM EDTA, sterile water) and the rest of the tube was filled with 8.6% sucrose. 
Sucrose gradients were centrifuged for 6 h at 100,000 g at 4°C and the crude endosomal 
fraction and Golgi/ER membrane fraction were collected. The percentage of each sucrose 
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solution (HB buffer, 35% and 62%) used in these experiments were accurately adjusted 
using a refractometer.    
 
7. Immunoprecipitation and Western blot analysis 
Cells were placed on ice and washed with Ca2+- and Mg2+-free phosphate-buffered 
saline (PBS), and the proteins were solubilized in 20 mM HEPES (Sigma, pH 7.6), 
containing 10 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA (Sigma), 1 mM EGTA (Sigma), 
0.5 mM phenylmethylsulfonyl fluoride (Sigma), 10 μg/ml of leupeptin (Roche), 10 μg/ml 
of aprotinin (Roche), 5 μg/ml of pepstatin A (Sigma), and 50 mM β-glycerophosphate 
(Sigma) for 15 min at 4 °C. Lysates were then centrifuged at 2,500 × g for 15 min to remove 
insoluble material. Cleared lysates were incubated with appropriate antibodies for 2 h, and 
precipitated using protein A- or G-Sepharose. Immunoprecipitates were denatured in the 
sample buffer at 95 °C, resolved by electrophoresis. Proteins were transferred from SDS-
polyacrylamide gels to nitrocellulose membranes and probed by Western blotting with 
various antibodies, followed by chemiluminescence detection (Bio-Rad). Several 
exposures were analyzed to determine the linear range of the chemiluminescence signals. 
Quantification was performed using the densitometry analysis mode of Image Lab software 
(Bio-Rad). 
 
8. Denaturing immunoprecipitation for ubiquitination assay 
Denaturing immunoprecipitation was performed as described previously [120]. 
Briefly, cells were lysed in denaturing buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% 
Triton, 1% SDS, 1 mM Na3VO4, 10 mM NaF, 10 μM MG132) and boiled for 10 min. 
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Lysates were diluted 1:10 with the same buffer without SDS and incubated with the 
appropriate antibody overnight with rotation at 4 °C. Protein G-agarose (GE Healthcare 
Life Sciences) was added, and the beads-agarose were washed four times in lysis buffer 
(without SDS). Proteins were eluted at 95 °C in SDS loading buffer, separated by SDS-
PAGE, transferred to nitrocellulose membrane, and probed by Western blotting with 
various antibodies, followed by chemiluminescence detection. 
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CHAPTER 3 
 “Hematopoietic and neural crest defects in zebrafish shoc2 mutants: 
 a novel vertebrate model for Noonan-like syndrome” 
 
 
Abstract 
 
The extracellular signal-related kinase 1 and 2 (ERK1/2) pathway is a highly 
conserved signaling cascade with numerous essential functions in development. The 
scaffold protein Shoc2 amplifies the activity of the ERK1/2 pathway and is an essential 
modulator of a variety of signaling inputs. Germline mutations in Shoc2 are associated 
with the human developmental disease known as Noonan-like syndrome with loose 
anagen hair (NSLH). Clinical manifestations of this disease include congenital heart 
defects, developmental delays, distinctive facial abnormalities, reduced growth and 
cognitive deficits, along with hair anomalies. The many molecular details of pathogenesis 
of the Noonan-like syndrome and related developmental disorders, cumulatively called 
RASopathies, remains poorly understood. Mouse knockouts for Shoc2 are embryonic 
lethal, emphasizing the need for additional animal models to study the role of Shoc2 in 
embryonic development. Here, we characterize a zebrafish shoc2 mutant, and show that 
Shoc2 is essential for development and that its loss is detrimental for neural crest 
development and for hematopoiesis. 
  
40 
 
Introduction: a novel vertebrate model for Noonan-like syndrome with loose anagen 
hair (NSLH). 
Patients diagnosed with  NSLH display abnormalities that are very broad 
phenotypically and often are more severe than patients with Noonan syndrome [153, 155, 
166, 167], raising the questions of how mutations in Shoc2 contribute to a syndrome with 
a wide-spectrum phenotype, and what are the biological activities regulated by Shoc2-
transmitted ERK1/2 signals. As a Shoc2 knockout in the mouse results in early 
embryonic lethality, additional animal models are needed to dissect the role of this 
important scaffolding protein during embryogenesis.  
To investigate the role of Shoc2 in tissue development and morphogenesis, we 
have exploited the powerful zebrafish model (Danio rerio). Zebrafish were first 
introduced as a vertebrate model system in early 1980s and since have emerged as an 
important genetic system to study normal human development [168-174]. Molecular 
pathways in zebrafish are highly conserved and 70% of human genes have orthologues in 
zebrafish, suggesting that most human pathogenesis could be modeled in zebrafish [172]. 
Zebrafish have most of the vital organs seen in humans such as brain, central nervous 
system, kidney, pancreas, liver, intestine, heart, ear, nose, muscle, skin, blood, 
vasculature, cartilage, and bones. Other advantages that make zebrafish a powerful 
vertebrate model include fast early development on the order of a few days, ability to 
generate a large number of progeny, and the external development and transparency of 
zebrafish embryos which enables monitoring and high-resolution imaging of very early 
developmental events. Zebrafishes’ external development allows them to be easily 
genetically manipulated. DNA, RNA, and morpholino can be readily injected into the 
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one-cell stage embryos [175].  Previous studies using zebrafish have played a key role in 
defining the core Ras-ERK1/2 pathway and have provided fundamental insights into the 
understanding of developmental abnormalities of other RASopathies [173, 176, 177].  
The study presented in this chapter shows that both morpholino-mediated 
knockdown and CRISPR/Cas9 mutagenesis of Shoc2 in zebrafish results in multiple 
deficiencies during embryogenesis, including gross defects in blood cell differentiation 
and abnormal craniofacial development. Our observations that shoc2 morphants and 
Shoc2 CRISPR/Cas9 mutants (crispants) have systemic defects in neural crest 
specification and hematopoiesis underscore the central role of Shoc2 in embryogenesis. 
Our finding that the loss of Shoc2 induces an array of developmental defects emphasizes 
its essential role in coordinating activities of the linear components of the ERK1/2 
pathway. Moreover, we have developed and characterized a heritable model of Shoc2 
that exhibits many of the clinical hallmarks associated with the RASopathies, which can 
now be used to decipher the molecular mechanisms underlying these diseases. 
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Results 
 
1. Shoc2 in zebrafish 
Bioinformatics searches identified one Shoc2 zebrafish orthologue that is highly 
homologous to human Shoc2 at the amino acid level, sharing 88% identity [111]. The 
zebrafish shoc2 gene contains 9 exons, is located to chromosome 22 and predicts a 62.7-
kDa protein of 561 amino acids. Comparison to the human Shoc2 protein sequences 
reveals significant conservation in the fold of the LRR domains, suggesting that these 
functional motifs have been conserved across evolution (Figure 3.2). To determine the 
temporal expression pattern of shoc2, we performed reverse transcription PCR (RT-PCR) 
using RNA templates obtained from embryos at 3, 6, 12, 24, 30, 48, and 72 hours post 
fertilization (hpf, Figure 3.3). RT-PCR confirmed that shoc2 is maternally inherited and 
is expressed through all the analyzed time points. Shoc2 protein expression at early stages 
was confirmed using specific antibodies (Figure 3.3). We also examined the expression 
of shoc2 by whole-mount in situ hybridization between the stages of 6 hpf and 2 dpf and 
found that shoc2 is expressed ubiquitously during early development. Notably, at 24 hpf 
shoc2 was expressed in the dorsal aorta and was detectable in the somite boundaries 
(Figure 3.4). 
 
2. Morpholino knockdown of shoc2 
To explore the function of Shoc2 during embryogenesis, we first used two 
different translation-blocking morpholino antisense (MOs) oligonucleotides to inhibit 
expression of shoc2 at early stages of development (Figure 3.5). The effectiveness of 
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gene knockdown by these translation blocking MOs was confirmed by western blot 
analysis, and showed that the shoc2 morpholino was highly efficient and its translation-
blocking activity lasted through 3 dpf (Figure 3.6). Western blots of 3 dpf whole-embryo 
extracts derived from shoc2 morphants also revealed a clear reduction of phospho-
ERK1/2 in knockdown embryonic tissue, confirming that Shoc2 depletion leads to 
decreased levels of phosphorylated ERK1/2 in zebrafish (Figure 3.6). Both MOs 
produced similar phenotypes when injected into 1-cell-stage embryos (data not shown), 
and MO1 was used for all subsequent analyses. A standard control MO was used to 
control for non-specific phenotypes resulting from the microinjection procedure. Survival 
of MO-injected and un-injected embryos between 8 and 24 hpf was not significantly 
different across shoc2 morphants (76.7±10.7%), control morphants (84.6±17.5%), and 
un-injected embryos (81.9±21.3%).  
Control and shoc2 MO-injected embryos were categorized based upon their 
morphology and developmental stage at 24 and 48 hpf using standard staging criteria 
[161]. At 24 and 48 hpf, morphological markers (including the presence or absence of a 
beating heart) were scored to determine the developmental stage. Nearly all embryos 
injected with the standard control MO were at the correct developmental stage at 24 hpf 
(98%) and showed no overt morphological changes. Among the shoc2 morphants without 
developmental delay (90%), the body shape, head shape, and presence/absence of 
pericardial effusion were scored at 48 hpf, and the embryos were categorized as mild, 
moderate or severe. Shoc2 morphants in the “mild” category displayed no developmental 
delay or overt morphological changes when compared to control morphants. This 
category represented a very small number of shoc2 morphants (2%). shoc2 morphants in 
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the “moderate” category were also at the correct developmental stage, but displayed mild 
body torqueing, with spinal curvature. Moderate category shoc2 morphants also 
displayed mild brain malformation, large yolks, and kinked tails. The majority of shoc2 
morphants were categorized as “severe” and displayed a body torque with malformations 
of the tail and brain, and showed reduced circulation of blood cells within the dorsal aorta 
and posterior veins. We did not observe profound alterations in shoc2 morphant heart 
structure; however, severe morphants did display a slightly faster, statistically significant 
heart rate at 72 hpf (Figure 3.7). All embryos in this category displayed enlarged yolks. 
This phenotype was observed in 94% of shoc2 MO1 injected embryos (n>200, from 4 
independent experiments). No pooling of red blood cells was observed at any site away 
from circulation in the shoc2 morphants.  
Since hematopoietic stem cells (HSCs) and angioblasts originate from shared 
pluripotent precursors, blood and blood vessel formation are closely related in early 
developmental stages [178]. Thus, we examined whether vascular angiogenesis was 
affected by Shoc2 knockdown. Shoc2 MOs were injected into zebrafish embryos in 
which endothelial cells were marked by the expression of green fluorescent protein 
(fli1a:EGFP), allowing for a more detailed analysis of vascular development [179]. At 
22–48 hpf, the major vessels, such as dorsal aorta, caudal artery, posterior cardinal vein 
and caudal vein appeared normal, indicating normal vasculogenesis (not shown). 
However, at 72 hpf defective vasculature branching was visible with the most significant 
changes in the sub-intestinal vein (SIV; Figure 3.8). The SIV of 90% (n = 61, from three 
independent experiments) of shoc2 MO-injected embryos exhibited reduced size/number 
of vessel branches and/or ectopic blood vessels when compared to the basal defect level 
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of control embryos. Vascular defects did not appear to correlate directly with cardiac 
defects, as we observed embryos with vascular abnormalities that did not display major 
pericardial effusion or valvular insufficiency as assessed by a to-and-fro movement of 
blood within the heart. 
The zebrafish hematopoietic system has been studied comprehensively. The 
genetic programs regulating the emergence of HSCs and blood development are largely 
conserved in mammals and zebrafish [174, 180, 181]. Zebrafish and mammals share 
major blood cell types that are generated from common lineages of HSCs and have two 
waves of hematopoiesis [181, 182]. The first wave, primitive hematopoiesis, occurs 
during early embryonic development and generates erythromyeloid progenitors (EMPs) 
that give rise to primitive erythrocytes and some primitive macrophages. The second 
wave, definitive hematopoiesis, gives rise to the HSCs that have the potential to both 
self-renew and generate all adult hematopoietic cell types [181, 182].  
 Primitive hematopoiesis of zebrafish occurs in two intraembryonic locations: the 
intermediate cell mass (ICM) and the anterior lateral mesoderm (ALM, Figure 3.1). Cells 
within the ICM differentiate into the endothelial cells of the trunk vasculature and 
proerythroblasts [183]. Concurrently, myelopoiesis is initiated in the ALM. Primitive 
erythropoiesis is regulated intrinsically by transcription factors expressed in erythroid 
cells and extrinsically by erythropoietin secreted from surrounding cells and tissues. The 
transcription factor gata-1a activates the expression of erythroid-specific genes to 
promote the production of erythrocytes and roughly, 300 gata-1-positive proerythroblasts 
in the ICM enter the circulation around 24 hpf and mature into erythrocytes. These 
primitive erythrocytes are morphologically different from adult zebrafish erythrocytes, 
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which have less cytoplasm and large elongated nuclei. Unlike mammalian erythrocytes 
that are nucleated only in their primitive wave and loose nucleus in the adult all zebrafish 
erythrocytes are nucleated. The primitive erythrocytes account for all circulating 
erythrocytes for the first 4 days post fertilization (dpf) [171, 174, 181-183].  
Similar to cells in the ICM, the cells in the ALM contribute to both blood and 
vascular development and express transcription factors including fli1a, gata-2, lmo2 and 
scl [174]. A subset of the cells in ALM expresses pu.1, a member of the ets family of 
transcription factors essential to the development of myeloid cells [184, 185].  
 
 
 
Figure 3.1 Hematopoietic ontogeny in the developing zebrafish embryo.  
Primitive erythrocytes develop in the ICM while the primitive macrophages arise in 
ALM. Later, HSCs emerge in the AGM region, migrate to the CHT and eventually see 
the thymus and kidney. ICM- intermediate cell mass, ALM-anterior lateral mesoderm, 
AGM- aorta gonad mesonephros, CHT- caudal hematopoietic tissue, HSCs- 
hematopoietic stem cells.  
 
 
The second wave, definitive hematopoiesis, takes place in the aorta-gonad-
mesonephros (AGM, Figure 3.1). During definitive hematopoiesis, HSCs emerge from 
the ventral wall of the dorsal aorta (DA) of the AGM region. HSCs are responsible for 
the production of all mature blood cells (erythrocytes, granulocytes, monocytes, 
lymphocytes and thrombocytes) [174, 181, 183]. The involved transcription factors (i.e. 
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c-myb and runx1) and signaling pathways that regulate the formation of HSCs in a 
zebrafish are well conserved with mammals. After its emergence, the AGM progenitor 
cells first migrate to the caudal hematopoietic tissue (CHT, Figure 3.1) which is located 
posterior to the yolk extension and stay intermediately. HSCs then move to the thymus 
where the lymphocytes mature. Finally, HSCs reach their final destination, the kidney 
marrow, which is the human equivalent of bone marrow (Figure 3.1) [186]. In the kidney 
marrow, HSCs undergo unlimited self-renewal and also differentiate to produce all 
hematopoietic cell types throughout the zebrafish lifetime [182, 187].   
To validate hematopoietic defects found in shoc2 morphants , I utilized o-
dianisidine staining to detect hemoglobin of erythropoietic cells [163, 188]. In control 
embryos, hemoglobin-positive cells were found soon after circulation started at 26 hpf, 
whereas shoc2 MO-injected embryos completely lacked o-dianisidine staining (Figure 
3.9.A). At 48-72 hpf erythrocytes in control embryo were robustly stained with o-
dianisidine and were prominent in the ducts of Cuvier, over the yolk sac, while in shoc2 
MO-injected embryos we observed a marked decrease in the intensity of o-dianisidine 
staining. I then tested the specificity of MO-induced phenotypes by a mRNA rescue 
assay. When wild type (WT) human shoc2 mRNA was co-injected with shoc2 MO, a 
rescue of shoc2 MO-induced defects in erythrocyte circulation defects was observed 
(Figure 3.1.B and C). Since the blood deficiencies were detected at the very early stages 
of hematopoiesis, I then tested whether other blood lineages were affected in shoc2 
morphants. Sudan Black B staining, which detects lipids in neutrophils and monocytes 
[189], was utilized to examine whether shoc2 depletion affected the myeloid lineage. A 
significant reduction in the number of neutrophils in caudal hematopoietic tissue (CHT) 
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of shoc2 morphants (93%, or 105/113 injected) in comparison with control-MO injected 
embryos at 72 hpf was detected (Figure 3.9.D), indicating that the depletion of shoc2 
causes defects in myelopoiesis. The cells positive for Sudan Black B staining were scored 
in 5 somites at the CHT region after the yolk extension (Figure 3.9.E). Together, these 
data suggest that Shoc2 is involved in general blood cell differentiation and possibly 
plays a role in both the primitive and definitive waves of hematopoiesis [190]. 
 
3. Generation of zebrafish shoc2 heritable mutants 
Although MO injections readily permit transient knockdown of gene expression, 
their efficacy is limited to the first few days post-fertilization. To gain a better 
understanding of the roles of Shoc2-mediated ERK1/2 signals during development, as 
well as allow for a quantitative phenotypic assessment, the CRISPR/Cas9 genome editing 
approach was employed to develop stable lines of zebrafish harboring germline mutations 
in shoc2 [162]. Using this approach, I engineered sgRNA directing gene editing to  
coding exons 2 and 3. Neither of the sites targeted by the sgRNAs overlapped with the 
MO target sites (Figure 3.10.A). Multiple independent target-specific mutant alleles for 
shoc2 were identified in the F1 generation (Figure 3.10.B). Mutations in the target region 
were confirmed by both high resolution melting analysis and sequencing analysis (Figure 
3.11). Each of the introduced mutations included a deletion and/or insertion within these 
coding exons, introducing a frameshift and premature stop codon that would be expected 
to truncate the Shoc2 protein. Zebrafish mutant lines harboring null mutations in exon 2 
(shoc2Δ22) and 3 (shoc2Δ14) were used in the following experiments. Both mutants carry 
frame-shift mutations (c.357-378, del and c.671-684, del) that truncate the protein by 121 
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and 229 amino acids, respectively, predicting the loss of a large portion of Shoc2’s LRR 
region (Figure 3.12.A). When shoc2 mRNA was assessed in homozygous shoc2Δ22 and 
shoc2Δ14 mutants, a corresponding reduction in the size of the amplified fragments was 
detected (Figure 3.12.B). Protein expression analyses using an antibody to Shoc2 
confirmed the loss of full-length Shoc2 in shoc2Δ22 and shoc2Δ14 alleles (Figure 3.13), 
while heterozygous Shoc2 alleles did not show decreases in Shoc2 protein (Figure 3.14). 
Importantly, we also observed decreased levels of pERK1/2 in shoc2Δ22 and shoc2Δ14 
mutant larvae (Figure 3.13). To avoid potential off-target effects, shoc2Δ22/+ and 
shoc2Δ14/+ mutants were outcrossed to WT for three generations prior to the further study. 
 Zebrafish heterozygous for either shoc2 mutant alleles were viable, fertile, and 
displayed no overt phenotypes. When heterozygous adults were in-crossed, no severe 
morphological defects were detected in the progeny prior to 5 dpf. However, at later 
stages of development, pleiotropic effects on larval morphology that became 
progressively severe were observed in the shoc2-/- larvae. At 6 dpf, 90–100% of shoc2 Δ22 
and shoc2 Δ14 mutant larvae developed edema of the heart cavity and along the trunk, yolk 
sac and yolk extension, around the eyes and became lethargic (Figure 3.15). The swim 
bladders of shoc2 Δ22 and shoc2 Δ14 larvae were underinflated and I observed a small but 
significant 1.25 fold increase in the heart beat of the severely edemic 6 dpf larvae when 
compared to WTs, the likely result of the increased edema at this stage. Further 
quantitative survival studies indicated that at 6 dpf, shoc2Δ22 and shoc2Δ14 larvae began to 
die, with none surviving beyond 9 dpf. All of WT and heterozygous larvae survived to 10 
dpf and displayed the expected Mendelian ratio for homozygous WT vs. Heterozygous 
genotypes (1:2) (Figure 3.16). Similar severe edema was observed for the compound 
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mutant of shoc2 Δ22 and shoc2 Δ14 (Figure 3.17). Because the observed defects manifested 
themselves at 5-6 dpf, we hypothesize that the presence of maternally inherited shoc2 
allow shoc2 crispants to develop somewhat normally during the first few days post 
fertilization. Taken together, these data demonstrate that loss of Shoc2 is detrimental to 
the embryonic zebrafish development. 
 
4. Effects of Shoc2 mutants on neural crest development 
Closer examination of shoc2Δ22 and shoc2Δ14 nulls indicated possible changes in 
craniofacial morphology. I found that at 6 dpf, shoc2 Δ22 and shoc2 Δ14 mutants were 
shorter in length than WT larvae, displayed smaller eye surface area, a narrow spinal 
cord, and had markedly abnormal craniofacial skeletons (Figure 3.18.A, B, and D). 
Morphological analyses of Alcian-Blue-stained samples revealed that shoc2Δ22 mutants 
exhibited a prominent defect in Meckel's cartilage, which in shoc2 Δ22 mutants curved 
downwards and did not extend as far anteriorly as that of WT larvae. Additionally, we 
found that the ceratohyal cartilage of shoc2 mutants were smaller and shifted farther 
posteriorly, or were missing entirely. To quantitatively evaluate the abnormality of the 
cartilage tissues, I analyzed the positional relationships between the Meckel's cartilage 
and the two ceratohyal cartilages, the length of ceratohyal arch, the angle between 
ceratohyals arch, and the total length of craniofacial cartilage structures (Figure 3.18.C). 
Significant changes were found in all of these parameters in shoc2 mutants, indicating 
that Shoc2-mediated signaling is required for proper signal transmission during the 
development of the craniofacial structures. 
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Intramembranous (dermal) and cartilage bones appear during early larval 
development. By 6 dpf, three ossified teeth and a number of pharyngeal arches and other 
ossified bone structures can be visualized by Alizarin Red S staining, which detects 
calcific deposition by cells of an osteogenic lineage (Figure 3.19) [191]. I next tested 
whether bones form normally in homozygous shoc2Δ22 and shoc2Δ14 mutant larvae. 
Alizarin Red S staining demonstrated a strong reduction in calcification of craniofacial 
bones. We found that parasphenoid, notochord, and branchiostegal ray 1 and 2 were 
completely missing and opercle, ceratobranchial, and cleithrum bones were significantly 
deformed/delayed in shoc2Δ22 and shoc2Δ14 null mutants (Figure 3.19 and 3.20). 
Together, these data suggest that Shoc2 also contributes to bone formation or remodeling.  
Interestingly, mutations in shoc2 also affected the pigmentation pattern of shoc2 
null larvae. At 6 dpf, WT larvae displayed a distinct uniform pattern of head and the 
lateral stripe melanophores (Figure 3.21). In contrast, shoc2Δ22 and shoc2Δ14 null larvae 
lost the regularity of melanophore patterning and presented with overlapping lentigines. 
The abnormal appearance of the melanophores in mutant larvae can be attributed to 
defects in patterning of regeneration and metamorphic melanophores, suggesting 
abnormal migration or differentiation of this lineage. Alternatively, this may be a result 
of a defective visual background adaption response due to the impairments in eye 
development. Collectively, these data suggest a defect in the development of the neural 
crest, which was corroborated by the findings that expression of the neural crest 
pluripotency marker foxd3 was increased in shoc2 null larvae (Figure 3.22). 
Additionally, high shoc2 expression in the sox10:RFP positive cells isolated from the 
Tg(sox10:RFP) transgenic fish was detected (Figure 3.23), indicating that Shoc2 may 
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regulate neural crest specification in a cell-autonomous manner. Given the only known 
function of Shoc2 is to accelerate ERK1/2 signals, we conclude that altered expression of 
foxd3 and neural crest cell development are the consequence of impaired Shoc2 function 
and resulting in decreased ERK1/2 activity. 
 
5. Effects of Shoc2 mutants on hematopoiesis 
Considering the blood phenotypes induced by the Shoc2 MO injections, I 
examined circulating blood in shoc2Δ22 and shoc2Δ14 null larvae. Consistent with the 
observations in the shoc2 morphants, o-dianisidine staining revealed a significant 
decrease in erythropoietic cells in shoc2Δ22 compared to WT larvae (Figure 3.24.A). 
Relative concentrations of hemoglobin were evaluated by the intensity of red color and 
scored in arbitrary units of intensity (a.u.i.) from 0 to 5, 0 being the weakest and 5 the 
strongest. The erythrocytes were scored in the ventral side of the head of the WT and 
shoc2Δ22 null larvae (Figure 3.24.B). To determine whether macrophage and neutrophil 
numbers were affected, histochemical staining for myeloperoxidase (mpx, an enzyme 
characteristic of neutrophil primary granules) was performed (Figure 3.24.C). The mpx-
positive cells located in 5 somites after the yolk extension were scored. Mpx-enzymatic 
activity assays detected a significant reduction in numbers of neutrophils in shoc2Δ22 and 
shoc2Δ14 null larvae when compared to the WT larvae (Figure 3.24.D and 3.25). The 
results of staining for mpx and hemoglobin indicate that the loss of Shoc2 abrogates 
differentiation of cells of different blood lineages. The observed changes were not likely 
due to the excessive apoptosis, since arcidine orange staining that visualizes apoptotic 
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cells showed no significant differences in shoc2Δ22 null larvae when compared to WT 
(data not shown). 
I next explored possible mechanisms for how Shoc2 regulates the differentiation 
of specific blood lineages. The transcription factors gata-1a, gata-2a, and pu.1 were 
reported to be early key factors in the process of primitive erythropoiesis and 
myelopoiesis. Quantitative transcription analysis using RNA isolated from WT, shoc2Δ22 
and shoc2Δ14 larvae was performed. Expression levels of gata-1a, gata-2a, mpx, and pu.1 
were significantly lower in mutant larvae compared to WT larvae. Moreover, expression 
levels of other markers of blood lineages such as l-plastin (leukocytes,[192]), rag-1 (B- 
and T-cells,[193]), lck (T-cells,[194]) were down-regulated approximately two-fold in 
shoc2 mutants (Figure 3.26). Similar changes in expression of the relevant transcription 
factors were detected for shoc2Δ14 mutants (Figure 3.27). Therefore, the gene expression 
data indicate that loss of shoc2 results in dysregulation of hematopoietic gene expression 
programs. Moreover, we found that shoc2 is highly expressed in gata1a:dsRed cells 
isolated from Tg(gata1a:dsRed) transgenic embryos (Figure 3.28), indicating that shoc2 
is present in erythroid progenitor cells and therefore may regulate definitive 
hematopoiesis cell-autonomously.  
Finally, I evaluated the morphology of circulating blood cells in detail in WT and 
shoc2 mutants. Individual WT and mutant 6 dpf larvae were bled, and peripheral blood 
cells were deposited on slides by centrifugation and then stained using the May-
Grünwald Giemsa method. The classification of normal teleost blood cells in various 
developmental stages is well-established [180]. Based on their distinct cell morphologies, 
we detected various sub-types of blood cells in both WT and mutant blood samples 
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(Figure 3.29). As expected, the majority of circulating cells were erythroid (Figure 
3.30). The erythroid cells in zebrafish, similarly to the other teleosts, are elliptical and 
possess compact nuclei and cytoplasm filled with hemoglobin with typical size of 7-
10µm [171]. Mutations in shoc2 caused severe anemia, as significantly fewer 
erythrocytes were detected in the circulation (Figure 3.30.A and B). In addition, 
erythrocytes of shoc2Δ22 6 dpf larvae were spherical, and had a considerably lower cell 
surface area as well as significantly smaller nuclei (Figure 3.30B, C, and D). Thus, 
based on general changes in blood cell numbers, loss of multiple blood lineages and 
altered erythrocyte surface area, the late pleiotropic phenotype of shoc2Δ22 larvae is 
associated with the loss of early ERK1/2 signals in hematopoiesis. 
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Figure 3.2 Homology models of zebrafish and human Shoc2, residues 79-561 and 79-582, 
respectively, were constructed using the published structure of Arabidopsis Flg22-FLS2-
BAK1 immune complex (PDB id: 4MN8) and Leptospira interrogans LRR protein 
LIC11098 (PDB id: 4U08) as templates for zebrafish and human Shoc2 models 
correspondingly. The modeling was done using the I-TASSER server and figures were 
prepared using PyMol software. 
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Figure 3.3 Shoc2 gene and protein expression in early development of zebrafish. (A) 
shoc2 mRNA was detected using RT-PCR at the indicated times. pu.1, atp5h and gapdh 
were used as reference genes. pu.1 was previously shown to express after 16 hpf. (B) 
Western blot analysis of zebrafish embryos. Embryos were harvested for immunoblotting 
at indicated time points. The expression of Shoc2 and GAPDH was analyzed using 
specific antibodies. GAPDH was used as a loading control.  
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Figure 3.4 Expression pattern of shoc2 in zebrafish embryonic development.  
RNA in situ hybridization with antisense probes for Shoc2 in WT embryos at 6, 12, 24 
and 48 hpf. An extensive anterior expression in the head region and the somite 
boundaries (black arrow) was observed at later stages (24 and 48 hpf). Images are in 
lateral views, anterior to the left.  
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Figure 3.5 Schematic representation of Shoc2 loci and MO targeting sites.  
Shoc2 intron-exon structure with two translation-blocking MOs targeting sites at exon 2 
are depicted. MO- Morpholino.    
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Figure 3.6 Western blot analysis of MO-injected embryos.  
Embryos injected with shoc2 and control MO were harvested for immunoblotting at 72 
hpf. The expression of indicated proteins was analyzed using specific antibodies. β-actin 
was used as a loading control.  
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                                       (C) 
 
Figure 3.7 Characterization of shoc2-MO injected embryos. (A) Representative body 
images of control and shoc2 morphants at 48 hpf. One-cell stage embryos were injected 
with the standard control MO and shoc2 ATG MO1. The optimal dose for microinjection 
of MO was determined as that which resulted in specific defects but did not cause gross 
lethality or global defects. As shown, at 48 hpf, 70.4% (57 out of 81) of shoc2 morphants 
displayed an enlarged hindbrain (arrowhead), enlarged yolk, and a posterior kink in the 
tail (arrow). (B) Representative body images of control and shoc2 morphants at 72 hpf. 
shoc2 MO-injected embryos showed reduced numbers of cells in circulation when 
compared to control embryos. (C) The cardiac heart rate of control and shoc2 morphants 
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was measured at 48 and 72 hpf. Significant difference in heart rate was observed in 
shoc2-morphants when compared to WT. Error bars represent means with SEM. ***p < 
0.001 and **p < 0.05 (Student’s t-test). MO- morpholino, hpf- hours post fertilization, 
M- DNA marker, PVC- posterior cardinal vein, DA- dorsal aorta.  
 
(Experiments performed by Marie Forbes-Osborne and analyzed by HyeIn Jang) 
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Figure 3.8 Disruption of zebrafish shoc2 results in vasculature defects.  
fli1a:EGFP embryos were injected with control  or shoc2 MO. Control embryo showed 
well-organized inter-segmental vessels, while embryos injected with shoc2 MO showed 
aberrant trunk blood vessels and disorganized sub-intestinal vein, indicated by arrow. All 
embryos shown in lateral view with anterior to the right and dorsal to the top. Images are 
taken at 3 dpf. 
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64 
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Figure 3.9 Number of erythropoietic and myelopoietic cells are affected in shoc2 
MO injected embryos. (A) o-dianisidine staining of hemoglobin in control and shoc2 
MO injected embryos at the indicated times (26, 48, and 72 hpf). In control embryos, 
hemoglobin-positive cells were found on the yolk sac soon after circulation starting at 26 
hpf, shoc2 morphants lacked staining completely. At 48 hpf the number of o-dianisidine 
positive cells was severely reduced in shoc2 morphants in comparison to control. (B) 
Injection of human shoc2 mRNA in shoc2 morphants. The data show rescue of 
hemoglobin phenotypes at 48 hpf. (C) Analysis of hemoglobin staining presented in (B). 
o-dianisidine positive area in the region of yolk and tail was assessed based on 
hemoglobin staining intensity. Number of embryos analyzed: 48 hpf cont-MO injected 
embryos, n=17; 48 hpf shoc2 MO, 5.24 ng/embryo, n = 84; 48 hpf shoc2 MO, 5.24 
ng/embryo plus 100 pg/embryo human shoc2 mRNA, n = 64. (D) Sudan Black B staining 
of myelopoietic cells (neutrophils) in control- and shoc2-MO injected embryos at 72 hpf. 
Significant reduction in circulating neutrophils was found in shoc2 morphants (93%, or 
105/113 injected). Insets show neutrophils in clumps in the CHT. Three biological 
replicates were performed for all experiments. (E) Analysis of Sudan Black B staining 
presented in D. Sudan Black B-positive cells were counted within the 5 somites of CHT 
region. Error bars represent means with SEM. ***p < 0.001 (Student’s t-test). hpf- hours 
post fertilization, MO- morpholino, CHT- caudal hematopoietic tissue. 
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       (B)  
 
 
Figure 3.10 Heritable mutations of the Shoc2 gene.  
(A) Zebrafish Shoc2 genomic locus on chromosome 22 with the DNA cleavage positions 
(in exon 2 and exon 3 indicated by the red bars). 
(B) Details of the F1 offspring genotypes. The F1 genotypes contain deletions (dashes) 
and insertions (red letters) at the shoc2 gRNA and #2 sites (orange letters) near proto-
spacer adjacent motif sequences (blue letters). The numbers of deleted or inserted base 
pairs and resultant frameshift mutations are indicated. The premature stop codons are 
underlined.  
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Figure 3.11 Detection of shoc2 mutant alleles in individual shoc2 sgRNA/Cas9 
injected embryos.  
The HRMA curve discriminates WT and mutant alleles. The genomic DNA was prepared 
from individual 1 day-post-injected embryos. The LightCycler® 480 High Resolution 
Melting Master and LightCycler® 96 system were used. The curves of embryos injected 
with shoc2 sgRNA/Cas9 targeting exon 2 (A) and exon 3 (B) were shifted and irregular, 
indicating the presence of insertions/deletions.  
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Figure 3.12 PCR analysis detecting shoc2Δ22 and shoc2Δ14 alleles. 
(A) PCR analysis of genomic DNA allows for sensitive detection of WT and shoc2Δ22 
and shoc2Δ14 mutant alleles in individual larvae (F3 generation). Acrylamide gel 
electrophoresis shows PCR amplicons of WT, heterozygous and homozygous shoc2Δ22 
and shoc2Δ14 carriers. (B) RT-PCR analysis allows for sensitive detection of WT and 
shoc2Δ22 and shoc2Δ14 mutant RNA in individual larvae. Acrylamide gel electrophoresis 
shows PCR amplicons of WT, heterozygous and homozygous shoc2Δ22 and shoc2Δ14 
carriers. M- DNA marker. 
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Figure 3.13 Immunoblot analysis of WT, shoc2Δ22 and shoc2Δ14 larvae.  
Larvae were harvested for immunoblotting at 6 dpf. Protein expression was analyzed 
using specific antibodies. β-actin was used as a loading control. 
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Figure 3.14 Expression of Shoc2 in WT and shoc2Δ22+/- zebrafish.  
Western blot analysis detects unaltered expression of Shoc2 protein in adult WT and 
shoc2Δ22+/- zebrafish.   
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Figure 3.15 Late pleiotropic phenotype of shoc2Δ22 and shoc2Δ14 crispants.  
Severe edema between the trunk and the yolk sac and yolk extension, heart and kidney, 
and underinflated yolk of 6 dpf shoc2Δ22 and shoc2Δ14 crispants are indicated with red 
arrows. Insets show severe eye edema of shoc2Δ22 and shoc2Δ14 crispants. Larvae are 
shown in dorsal or lateral view. Larvae were positioned and imaged live with the 
Vertebrate Automated Screening Technology (VAST) platform (Union Biometrica) 
[195]. Larvae were anaesthetized with 0.2 mg/mL tricaine prior to being loaded into the 
sample reservoir. Dorsal and lateral images were acquired at a >70% minimum similarity 
from the pattern-recognition algorithm. High-resolution frontal and posterior images were 
stitched together using Adobe Photoshop CS6. For each larva shown, 3.5-fold magnified 
views of the eye region are displayed. 
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Figure 3.16 PCR analysis of genomic DNA of shoc2Δ22 and shoc2Δ14 inbred larvae at 
9 dpf. Progeny of three independent inbreeding experiments using heterozygous shoc2Δ22 
and shoc2Δ14 fish were genotyped. All survival larvae were genotyped as either WT or 
heterozygous carriers of the shoc2Δ22 and shoc2Δ14 crispant allele. Three biological 
replicates were performed for both alleles.  
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Figure 3.17 shoc2Δ22-shoc2Δ14 compound mutants develop edemic phenotype.  
shoc2Δ22+/- and shoc2Δ14+/- adult fish were crossed to generate shoc2Δ22-shoc2Δ14 
compound mutants. (A) Images of 6 dpf compound crispants show edemic phenotype 
similar to the observed in shoc2Δ22 and shoc2Δ14 crispants. Red arrows indicate edema 
around the eye, heart/yolk region of the larva. (B) PCR analysis of genomic DNA 
confirms the deletions in both alleles: exon2 with 22 bp deletion and exon3 with 14 bp 
deletion. M- DNA Marker. CM- compound mutant.  
 
(Experiments performed by Rebecca Norcross and analyzed by HyeIn Jang) 
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Figure 3.18 shoc2 loss leads to defects in craniofacial cartilage specification and 
differentiation.  
(A) Lateral and ventral views of a 6 dpf WT and shoc2Δ22 crispant larvae after Alcian 
blue staining. Mutant larvae show significant changes in head cartilage.  
(B) Schematic representation of the different head cartilage elements in ventral view of 6 
dpf. anterior limit (an), articulation (ar), ceratobranchial pairs 1 to 4 (cb1-4), ceratohyal 
(ch), ethmoid plate (et), hyosymplectic (hs), Meckel's cartilage (mk), palatoquadrate (pq), 
posterior limit (po).  
(C) Schematic representation of parameters quantified; length of ceratohyal (CH) and CH 
to Meckel’s cartilage (mk), angle of CH, pupillary distance (pu), eye surface area, width 
of vertebral column and length of total face cartilage (red arrows) were measured for 
morphometry. Y-axes on graphs indicate the fold change of shoc2Δ22 crispants compared 
to WT.  
(D) Measured distance between the eyes and the eye surface area of 6 dpf WT and 
shoc2Δ22 crispant larvae. Three biological replicates were performed for all experiments 
(n= 20/group). (**p < 0.05, Student's t- test). Error bars represent means with SEM. A- 
anterior, P- posterior. 
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Figure 3.19 Bone development is impaired in shoc2Δ22 crispant larvae.  
(A) Lateral view of a 6 dpf WT and shoc2Δ22 crispant larvae detected by Alizarin Red S 
staining. Mutant larvae show significant differences in cranial bone formation.  
(B) Schematic representation of the different cranial bone elements detectable at 6 dpf: 
branchiostegal ray 1 and ray 2 (br1 and br2), notochord (n), opercle (o), parasphenoid (p) 
and ceratobranchial 5 (cb). Ventral view of 6 dpf WT and shoc2Δ22 larvae stained with 
Alizarin Red S. Detected changes include defects in ossification of parasphenoid, 
ceratohyal, branchiostegal rays, opercle, ceratohyal and notochord. Three biological 
replicates were performed for all experiments (n= 30/group).  
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Figure 3.20 Bone development is impaired in shoc2Δ14 crispant larvae.  
Lateral and ventral view of a 6 dpf WT and shoc2Δ14 crispant larvae detected after 
Alizarin Red S staining. Mutant larvae show significant differences in cranial bone 
formation.  
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Figure 3.21 Pigmentation pattern of shoc2 null larvae.  
Dorsal (head) and lateral (trunk) views of 6 dpf larvae showing melanophores in WT and 
shoc2Δ22 (A), and shoc2Δ14 (B) crispants. shoc2-/- mutants presented with closed gaps in 
pigmentation pattern of head and lateral stipe (brackets) melanophores when compared 
with WT controls.  
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Figure 3.22 Levels of foxd3 mRNA expression quantified by qPCR.  
The data are presented as the fold change of the mRNA levels in WT larvae versus the 
mRNA levels in mutant larvae. ath5 is a control mRNA. The results represent an average 
of three biological replicas. Error bars indicate means with SEM. **p < 0.05 (Student’s t-
test).  
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Figure 3.23 shoc2 expressed in neural crest cells.  
sox10:RFP positive cells were isolated from the transgene adult fish using flow 
cytometry. FACS profile of sox10:RFP are shown. Red boxes indicate the collected cell 
populations. Total RNA was isolated and RT-PCR was performed. RT-PCR detected 
shoc2 in both sox10-positive flow-sorted cells. foxd3 is included to confirm the 
specificity of flow sorting. M- DNA Marker.  
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Figure 3.24 Impaired hematopoiesis in shoc2Δ22 crispant larvae.  
(A) o-dianisidine staining detecting hemoglobin of erythropoietic cells in control and 
shoc2Δ22 larvae at 6 dpf. In control, larvae hemoglobin-positive cells were found on the 
yolk sac and tail while shoc2Δ22 crispants showed significantly decreased number of cells. 
Images are shown in lateral and ventral view.  
(B) Quantitative analysis of the number of erythropoietic cells in circulation. Relative 
intensity of hemoglobin staining was scored in arbitrary units of intensity 0 to 5, 0 being 
the weakest and 5 the strongest. **p < 0.05 (Student’s t-test). 
(C) Histochemical staining for mpx enzyme activity in WT and shoc2Δ22 at 6 dpf. Larvae 
are shown in lateral view with the anterior to the left. The images are representative of ≥ 
20 larvae in each group. The staining was repeated with similar results for three 
independent experiments. Arrows point to mpx-positive cells.  
(D) The number of mpx-positive cells within the indicated box (5 somites). Error bars 
represent means with SEM. ***p < 0.001 (Student’s t-test). 
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Figure 3.25 Histochemical staining for mpx enzyme activity in 6 dpf WT and 
shoc2Δ14 crispants. Larvae are shown in lateral view with the anterior to the left. The 
images are representative of ≥ 20 larvae in each group. The staining was repeated with 
similar results for three independent experiments.  
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Figure 3.26 Loss of shoc2 causes a reduction in the expression of blood cell markers.    
qPCR analysis of blood lineage markers. Total RNA was extracted from 6 dpf WT and 
mutant larvae and levels of mRNA expression were quantified by qPCR. The data are 
presented as the fold change of the mRNA levels in WT larvae versus the mRNA levels 
in mutant larvae. ath5 is a control mRNA. The results represent an average of three 
biological replicas. Error bars indicate means with SEM. **p < 0.05 (Student’s t-test).  
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Figure 3.27 Loss of shoc2 causes a reduction in the expression of blood cell markers.  
The relative changes in the expression of hematopoietic markers were evaluated in 
shoc2Δ14 crispants. Total RNA was extracted from 6 dpf WT and mutant larvae and levels 
of mRNA expression were quantified by qPCR. The data are presented as the fold change 
of the mRNA levels in WT larvae versus the mRNA levels in mutant larvae. ath5 is a 
control mRNA. The results represent an average of three biological replicas. Error bars 
indicate means with SEM. **p < 0.05 (Student’s t-test). 
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Figure 3.28 shoc2 is expressed in hematopoietic cells.  
gata1a:dsRed positive cells were isolated from adult fish using flow cytometry. FACS 
profile of gata1a:dsRed is shown. Red box indicates the collected cell populations. Total 
RNA was isolated and RT-PCR was performed. RT-PCR detected shoc2 in flow-sorted 
cells. gata1a was included to confirm the specificity of flow sorting. M- DNA Marker.  
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Figure 3.29 Blood cell types found in 6 dpf larvae. 
Peripheral blood cells from (A) WT and (B) shoc2Δ22 larvae at 6 dpf stained with May-
Grünwald Giemsa. Blood cells isolated from six WT or six shoc2Δ22 larvae were cytospun 
onto a coated slide and stained. Various blood cell subtypes were detected in both WT 
and shoc2Δ22 larvae.  
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Figure 3.30 Loss of shoc2 causes a reduction in the number of circulating blood 
cells.   
(A) Cytology of blood cells from WT and shoc2Δ22 larvae at 6 dpf. Peripheral blood cells 
isolated from six WT or six shoc2Δ22 larvae were cytospun onto a coated slide and stained 
by the May-Grünwald Giemsa method. The shoc2Δ22 larvae had significantly lower 
numbers of blood cells than WT larvae. Erythrocytes from 6 dpf WT larvae show the 
typical elliptical morphology, while the shoc2Δ22 cells were smaller and more circular in 
shape. Images were taken with a Leica DFC 7000 T camera with a 100x oil objective and 
10x eyepiece. 
(B) Total number of blood cells from samples in (A) is shown. The results represent an 
average of three biological replicas. n represents a number of fields used for scoring. 
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(C) Total surface area and (D) surface area of nuclei of erythrocytes from WT and shoc2 
knockout cells were measured and graphed. All calculations were performed using the 
morphometry mask statistics modules of the Slidebook 6.0 software. The results 
represent an average of three biological replicas. Error bars represent means with SEM. 
***p < 0.001 (Student’s t-test). 
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Table. 1. RT-PCR of hematopoietic and non-hematopoietic genes.  
RT-PCR of cells and WT, shoc2Δ22 and shoc2Δ14 larvae. Genes are indicated to the left; 
atp5h is used as a reference gene. Primer sequences are to the right of each gene.  
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Chapter 4 
 
Title:  
Shoc2 couples the E3 ligase HUWE1 with VCP/p97  
to control ERK1/2 signaling 
 
 
Abstract 
 
The pivotal role of the scaffolding protein Shoc2 in controlling ERK1/2 signals is 
underscored by its role in the pathogenesis of Noonan-like developmental syndrome. 
However, the molecular mechanisms regulating signal transmission via this intricate 
signaling module remain unclear. Here we identify that Shoc2 scaffold, through its 
leucine repeats rich domain, brings together the hexameric AAA+ ATPase VCP/p97 and 
the E3 ligase HUWE1 to modulate the levels of the HUWE1-mediated allosteric 
ubiquitination of Shoc2 and RAF-1. Abrogated activity of VCP/p97 ATPase leads to the 
increased presence of HUWE1 in the Shoc2 complex, followed by augmented 
Shoc2/RAF-1 ubiquitination and altered RAF-1 phosphorylation. We found that in 
fibroblasts from patients with Inclusion Body Myopathy with Paget’s disease of bone and 
Frontotemporal Dementia (IBMPFD) that harbor germline mutations in VCP/p97, the 
levels of Shoc2 ubiquitination and ERK1/2 phosphorylation are imbalanced. This study 
provides a mechanistic basis for the critical role of VCP/p97 in regulating the ERK1/2 
pathway and reveals a previously unrecognized function of the ERK1/2 pathway in the 
pathogenesis of IBMPFD.  
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Introduction 
 
During the past decade, a solid body of literature has demonstrated the functional 
significance of the molecular chaperone Valosin-containing protein (VCP) also known as 
p97 or Cell Division Cycle 48 (cdc48) in yeast [196, 197]. VCP is an ATPase Associated 
with a variety of cellular Activities (AAA+) –ATPase protein motor protein that is 
expressed in the cytosol, membrane-bound organelles (Golgi, ER, endosomes), and in the 
nucleus. Best known for its function in endoplasmic reticulum associated protein 
degradation (ERAD), VCP is involved in various cellular processes regulating a 
perplexing range of cellular functions. VCP helps remove misfolded proteins at different 
locations to protect the cell from protein stress, eliminate regulatory proteins in various 
intracellular signaling pathways including those that govern chromatin remodeling, DNA 
replication and repair, and facilitate proteasome-independent degradation in the lysosome 
by controlling protein sorting in the endocytic pathway and by regulating autophagy. 
[198-200]. Overall, VCP has emerged as a central and important element of the ubiquitin 
system with the majority of VCP substrates being ubiquitinated [201, 202]. 
Ubiquitination can be simply described as a three-step process catalyzed by three classes 
of enzymes: ubiquitin activating enzyme E1, ubiquitin conjugating enzyme E2, and 
ubiquitin ligase E3 which confers substrate specificity. Well-known for their role in 
protein degradation, ubiquitin marks have also been shown to contribute to the 
mechanisms regulating cellular signaling cascades and catalytic activities of signaling 
proteins [203, 204].  
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 The incredible diversity of VCP functions is achieved through a multitude of 
regulatory co-factors that dictate subcellular localization, oligomeric state of VCP, and 
substrate specificity [202, 205-209]. Importantly, VCP/p97 functions as an unfoldase, or 
“segregase” in processes such as DNA replication, nuclear and Golgi membrane 
assembly, and non-proteasomal degradation through macroautophagy and the 
endolysosomal pathway [197]. The molecular mechanisms underlying the “segregase” 
activity of the ring-shaped hexameric VCP assembly rely on the conformational changes 
induced by ATP binding and hydrolysis by the two ATPase domains D1 and D2 that 
follow the N-terminal domain (Figure 4.1.A) [197]. VCP forms stacked hexameric rings 
formed by the D1 and D2 domains with the N-domain on the outside of the D1 ring. This 
structural arrangement of domains allows the N-domain of VCP to interact with different 
cofactors. The AAA+ modules (D1 and D2) encompass the consensus Walker A and 
Walker B motifs that are critical for ATP binding and ATP hydrolysis, respectively. ATP 
hydrolysis in D2 seems to generate the main force of ATPase activity, while D1 
participates in substrate binding and stabilizes unfolded proteins [197, 210, 211]. It is 
believed that the conformational changes of the VCP molecule driven by ATPase activity 
generate mechanical movement that is responsible for the VCP function [196, 211]. VCP 
itself contains an intrinsic ubiquitin-binding site in its N-domain with low affinity for 
ubiquitin. Similarly, many cofactors of VCP also bear ubiquitin-binding domains [201, 
202, 206]. These additional ubiquitin binding sites enhance the affinity of VCP for 
ubiquitinated substrates [197]. It has been shown that all thirteen mammalian UBX 
(Ubiquitin regulatory X) domain-containing proteins serve as cofactors for VCP and 
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recruit substrates to VCP and regulate their fate [202]. Moreover, it has been established 
that VCP interacts with several single RING-and HECT-domain E3 ligases [212, 213]. 
As VCP governs critical steps in ubiquitin-dependent protein quality control and 
intracellular signaling pathways, it is not surprising that defects in VCP and its binding 
partners contribute to various diseases [196, 214, 215]. Germline mutations in VCP cause 
an autosomal dominant and fatal familial multi-systemic disease, Inclusion Body 
Myopathy with early-onset Paget disease and Frontotemporal Dementia (IBMPFD, 
OMIM #167320) that is characterized by incomplete penetrance of three main features: 
disabling muscle weakness, osteolytic bone lesions consistent with Paget’s disease, and 
frontotemporal dementia [196, 215, 216]. A majority of IBMPFD-associated VCP/p97 
mutants alter structural orientation between the VCP N- and D1 domains, thus altering 
the recognition by cofactors and/or ATPase activity [196, 215]. At the cellular level, 
IBMPFD is characterized by the impairments in protein degradation and accumulation of 
the ubiquitinated protein aggregates as well as several other cellular defects, but the 
molecular basis underlying these cellular abnormalities remains elusive. Currently, there 
is no cure for IBMPFD and the only treatment offered to patients merely alleviates the 
disease symptoms.  
Being a key mediator of several major protein homeostasis processes, VCP has 
also emerged as an attractive target for anti-cancer therapy [217, 218]. Recent advances 
in developing of a selective ATP-competitive inhibitor has given rise to a small-molecule 
compound, CB-5083, that induces a strong antitumor response in solid tumors and is 
currently being evaluated in clinical trials [218-223]. 
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In this study, we have found that VCP/p97 modulates signals of the canonical 
extracellular signal-regulated kinase (ERK1/2) pathway transduced by remodeling the 
Shoc2-scaffolding module. Earlier studies in Galperin lab showed that Shoc2 assembles 
an intricate scaffolding complex that incorporates canonical signaling enzymes (i.e. Ras, 
RAF-1 and the catalytic subunit of protein phosphatase 1c (PP1c)) as well as the proteins 
of the ubiquitin machinery, the E3 ligase HUWE1 and AAA+ ATPase PSMC5 [116, 
120]. Together these proteins create an elegant mechanism that both accelerates and fine-
tunes the amplitude of the ERK1/2 signals in a spatially-defined manner. Specifically, in 
the Shoc2 module, the E3 ligase HUWE1 catalyzes the ubiquitination of Shoc2 and RAF-
1 to provide a negative-feedback mechanism that modulates activity of the ERK1/2 
pathway. Consequently, PSMC5 triggers an essential redistribution of the Shoc2 
complexes to late endosomes/multivesicular bodies (LE/MVBs) where HUWE1 is 
sequestered from the scaffolding complex [116, 120]. Here, I demonstrate that VCP/p97 
is critical for the proper remodeling of the Shoc2 signaling complex and a subsequent 
tuning of the ERK1/2 signals via the Shoc2–Ras–RAF-1 complex. We provide evidence 
that in Noonan-like patients, Shoc2 aberrantly localized to the plasma membrane is 
inaccessible to VCP/p97, preventing proper complex remodeling. Importantly, our 
findings demonstrate that the alterations in Shoc2 ubiquitination and ERK1/2 
phosphorylation are important elements of IBMPFD pathology.   
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Results 
 
1. VCP/p97 is a novel partner in the Shoc2 scaffold module 
Earlier studies in the Galperin lab identified several proteins of the ubiquitin 
machinery including the previously reported E3 ligase HUWE1 and the AAA+ ATPase 
PSMC5 as interacting partners of Shoc2. This yeast two-hybrid screen of the human 
adult/fetal heart library also detected the twenty-nine cDNA prey fragments covering 
amino acids 180-390 of the 97 kDa AAA+ ATPase VCP/p97. All of the isolates extended 
over the carboxyl-terminus of the N domain and part of the D1 domain connected by the 
inter-domain linker (N-D1) of VCP (Figure 4.1.A).  
To validate the Shoc2 and VCP interaction, we co-expressed glutathione S-
transferase (GST)-fused Shoc2 (GST-Shoc2) and GFP-tagged VCP (VCP-GFP) in HEK 
293FT cells. VCP was detected in the GST immunoprecipitate, indicating the association 
of VCP and Shoc2 (Figure 4.1.B). HA-tagged M-Ras/Shoc2 immunoprecipitation was 
used as a positive control [110, 120]. Co-immunoprecipitation of endogenous Shoc2 with 
VCP, PSMC5 and ectopically expressed YFP-M-Ras from HEK 293FT cells showed that 
these proteins form a quaternary complex (Figure 4.1.C). Since VCP is often associated 
with the recognition of ubiquitinated substrates [224], we utilized a previously 
characterized Shoc2 7KR (seven Lys mutated to Arg) mutants in which ubiquitination is 
reduced 70- 80% compared to that of WT Shoc2 [120]. Immunoprecipitation experiments 
were performed using Cos1 cells stably expressing either WT or the 7KR mutant of 
Shoc2-YFP and depleted of endogenous Shoc2 [120]. The presence of VCP in the Shoc2 
7KR mutant immunoprecipitate decreased dramatically, indicating that VCP recognizes 
ubiquitinated Shoc2 (Figure 4.1.D). To map the interaction region of Shoc2 with VCP, 
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we utilized an HA-tagged VCP with tagRFP (tRFP)-tagged Shoc2 mutants generated in 
our previous studies [111]. The immunoprecipitation assay revealed that the leucine rich 
repeats 12-14 (aa 347-417) of Shoc2 mediate the association with VCP (Figure 4.2). 
Interestingly, this region of Shoc2 was earlier reported as the binding domain of HUWE1 
(Figure 4.2.E) [120]. Together, these results demonstrate that VCP is a previously 
unrecognized interacting partner in the Shoc2–Ras–RAF-1 signaling scaffold complex.  
 
2. VCP/p97 and Shoc2 colocalize on late endosomes and/or multivesicular bodies 
The Shoc2 multi-protein complexes are targeted to endosomes upon activation of 
the ERK1/2 pathway [122]. To delineate what role VCP plays in cellular distribution of 
the Shoc2 module, we analyzed the localization of Shoc2-VCP complexes using 
complementary methods of subcellular fractionation and fluorescence microscopy 
(Figure 4.3). A crude endosomal (late and early endosomes) fraction (CE) of Cos1 cells 
were enriched using a discontinuous sucrose density gradient centrifugation at the 8/35% 
interface of the gradient [165]. The distribution of key markers of early endosomes 
(EEA1/Rab5) and plasma membrane (Na+/K+-ATPase) indicates that CE as well as Golgi 
and endoplasmic reticulum (G/ER) fractions were free of any significant amount of 
plasma membranes (Figure 4.3.A). We found that VCP can readily precipitate Shoc2 
from the recovered CE protein interface, indicating that VCP is redistributed to the 
endosomes together with Shoc2 (Figure 4.3.B). The total amount of homogenate was 
comparable to the amount of total lysate used in immunoprecipitation experiments in 
Figure 4.1. Furthermore, we examined localization of VCP-GFP in cells stably depleted 
of endogenous Shoc2 and expressing Shoc2-tRFP together with the oligomeric PSMC5 
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(GST-PSMC5) that triggers Shoc2 recruitment to late endosomes/multivesicular bodies 
(LE/MVBs) [116]. Immunofluorescence microscopy revealed that the majority of Shoc2-
tRFP- and GST-PSMC5 positive vesicles contained VCP-GFP as well (Figure 4.3.C). 
Many of the Shoc2-tRFP/GST-PSMC5/VCP-GFP-positive vesicles often contained the 
multi-membrane intra-luminal branches characteristic of large multivesicular bodies 
(MVBs) and in some instances reached 4-5 μm in size, probably as a result of membrane 
fusion induced by the accumulation of Shoc2-PCMC5 complexes. These vesicular 
structures were previously characterized as the late endosomal compartments [116, 122]. 
Interestingly, the ATPase activity deficient QQ mutant of VCP (E305Q, E578Q) was also 
easily detectable on the Shoc2-PSMC5 positive endosomes (Figure 4.3.C), suggesting 
that enzymatic activity of VCP has no effect on Shoc2 complex subcellular distribution. 
To support this assumption, I analyzed the endosomal distribution of the Shoc2 7KR 
mutant. I found that while deficient in VCP association, the Shoc2 7KR mutant can be 
recruited to endosomes as effectively as its WT counterpart (Figure 4.4.A and B).   
Next, I explored the subcellular localization of the Shoc2-VCP complexes 
utilizing a Shoc2 S2G mutant found in patients with Noonan-like syndrome [152]. This 
S2G substitution in Shoc2 results in the aberrant N-terminal myristoylation and a plasma 
membrane targeted protein. VCP was not detectable in the Shoc2 immunoprecipitates 
obtained from the stable cells depleted of endogenous Shoc2 and expressing the S2G 
Shoc2-tRFP mutant (Figure 4.3.D), indicating that Shoc2-VCP complexes are formed in 
a spatially-defined manner. Findings in Figure 4.3.D were confirmed by the 
immunofluorescence microscopy (Figure 4.3.E). To confirm that correct spatial 
distribution of the Shoc2 complex is required for the Shoc2-VCP association, I utilized 
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the Shoc2 Δ21-C mutant lacking the PSMC5 binding domain and deficient in its ability 
to recruit the Shoc2 complexes to the endosomal compartment [116]. Results in Figure 
4.3.F show that this mutant was impaired in its ability to associate with VCP as well. 
Given that the Shoc2 Δ21-C mutant is markedly over-ubiquitinated [116], this data 
indicated that endosomal localization of VCP is essential for the remodeling of the Shoc2 
complex. 
 
3. VCP modulates ubiquitination of Shoc2 in the complex on endosomes 
To delineate mechanisms underlying the remodeling activity of VCP in the Shoc2 
complex, we evaluated whether the ATPase activity of VCP was involved in the 
assembly of the Shoc2 module. ATPase activity deficient QQ mutant of VCP (amino 
residues) and VCP ATP-competitive chemical inhibitor CB-5083 were utilized [219-
222]. Of note, cell treatment with CB-5083 has no effect on the levels of the proteins in 
the Shoc2 complex (Figure 4.5). CB-5083 was reported to not inhibit the ATPase 
activity of PSMC5 [219]. When examining the Shoc2-VCP interaction in cells expressing 
either the WT or QQ mutant of VCP-GFP, we detected increased amount of the VCP QQ 
mutant in the complex with Shoc2 (Figure 4.6.A). Similarly, increased amounts of VCP 
were found in GST-Shoc2 precipitate from cells treated with the CB-5083 inhibitor 
(Figure 4.6.B). Next, I assessed the interaction of Shoc2 with its other interacting 
partners in cells treated with CB-5083, RAF-1, PSMC5 and HUWE1. Interestingly, while 
the loss of ATPase activity had no effect on the ratio of RAF-1 and PSMC5 in the Shoc2 
complex, we found increased amounts of VCP and the E3 ligase HUWE1 associated with 
Shoc2 in cells treated with CB-5083 (Figure 4.6.C). Given that the Shoc2 recognition 
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domains by VCP and HUWE1 overlap, I then explored the possibility that VCP and 
HUWE1 bind to the scaffold competitively. Indeed, in the cells depleted of HUWE1, 
increased amounts of VCP immunoprecipitated with Shoc2 (Figure. 4.6.D). These results 
suggest that VCP may potentially compete with HUWE1 and that ATPase activity of 
VCP plays an important role in the assembly/disassembly or “segregation” of the Shoc2 
signaling module.   
The E3 ligase HUWE1 mediates ubiquitination of Shoc2 and RAF-1 [120], thus 
our data strongly indicates that the ATPase activity of VCP may regulate the levels of the 
Shoc2 and RAF-1 ubiquitination catalyzed by HUWE1. In order to examine this scenario, 
we treated the cells with CB-5083 and examined the ubiquitination of Shoc2 and RAF-1. 
As expected, the levels of Shoc2 (Figure 4.7.A) and RAF-1 (Figure 4.7.B) 
ubiquitination were increased significantly either in cells treated with CB-5083 or cells 
expressing the VCP QQ mutant (Figure 4.8). 
Studies in the Galperin lab have previously established that HUWE1-mediated 
Shoc2 ubiquitination is induced upon EGFR activation and its time-course closely 
follows the ERK1/2 phosphorylation curve (Figure 4.7.C, lanes 1-4) [120]. Conversely, 
in cells treated with CB-5083, ubiquitination of Shoc2 sustained irrespective of the EGFR 
activation status (Figure 4.7.C, lanes 6-8). Subsequently, CB-5083 treatment led to the 
accumulation of VCP and HUWE1 in the Shoc2 immunoprecipitate from the endosomal 
fractions (Figure 4.7.D). The levels of the ubiquitinated Shoc2 precipitated from the 
endosomal fraction of the cells treated with CB-5083 were also significantly higher than 
in control cells, while the overall ubiquitination of the proteins in the CE fraction was 
comparable (Figure 4.7.E).  
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 Surprisingly, these experiments also revealed that the amplitude of phosphorylated 
ERK1/2 in cells treated with CB-5083 was higher than in control cells. These findings were 
inconsistent with the previously understood role of Shoc2-ubiquitination as being a 
negative-feedback mechanism to reduce ERK1/2 activation [120]. Thus, I examined the 
activation of the RAF-1 kinase coupled with Shoc2 scaffold. Phosphorylation of RAF-1 at 
Ser338 was compared in Shoc2 precipitates from the cells treated with CB-5083 or control 
cells. As shown in Figure 4.7.F, in control cells, phosphorylation of the Shoc2-bound 
RAF-1 increased 2-fold in response to EGFR stimulation. However, in the cells treated 
with CB-5083, no changes in RAF-1 phosphorylation were observed even though total 
levels of phospho-ERK1/2 were higher in the inhibitor treated cells. Given the multitude 
of VCP-controlled cellular functions, it is possible that loss of the VCP-ATPase activity 
deregulates negative feedback loops targeting other components of the ERK1/2 network, 
or rather, induces activation of ERK1/2 via the alternative signaling loop or kinases other 
than RAF-1. Teasing apart precise loops that activate ERK1/2 upon CB-5083 inhibition 
will require further investigation. Nevertheless, we conclude that in the Shoc2 scaffolding 
module, VCP is likely to regulate HUWE1-mediated Shoc2 ubiquitination by sequestering 
the E3 ligase HUWE1 from the complex. Taken together, these data suggests that VCP is 
recruited to the endosomal compartment together with Shoc2 where it exerts its 
mechanoenzyme activity to remodel the Shoc2 scaffolding complex, regulate the Shoc2-
routed RAF-1/ERK1/2 activation, and possibly “reactivate” the Shoc2 complex. 
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4. The Shoc2/ERK1/2 nexus in IBMPFD pathogenesis  
IBMPFD-causing mutations have significant effects on substrate processing 
[225]. Hence, we tested whether the most-common disease-related mutation of VCP 
(Arg155His) [197, 214, 215] affects levels of Shoc2 ubiquitination. Expression of the 
VCP R155H mutant in Cos 1 cells led to increased levels of Shoc2 ubiquitination, while 
expression of its WT counterpart rather had an opposite effect on ubiquitination of Shoc2 
(Figure 4.9.A). Finally, to analyze the VCP-Shoc2 interaction under the pathologically 
relevant conditions, we utilized cultured primary fibroblasts from three IBMPFD patients 
expressing VCP proteins altered in the mutational hotspot, R155H. Fibroblasts from two 
healthy relatives were used as controls. The levels of Shoc2 ubiquitination were 
significantly higher in immunoprecipitates from lysates of IBMPFD fibroblasts when 
compared to lysates from healthy fibroblasts (Figure 4.9.B). I also observed that steady-
state levels of phospho-ERK1/2 were significantly higher in IBMPFD fibroblasts, which 
was reminiscent of the results in Figure 4.7.C and F, cell treatment with VCP inhibitor. 
This data further indicates that aberrations in VCP function might trigger compensatory 
network responses that are no longer under the tight fine-tuning of the Shoc2 scaffold.  
To confirm this hypothesis, we depleted Shoc2 in IBMPFD fibroblasts and 
examined the phospho-ERK1/2 response (Figure 4.9.C). As expected, siRNA depletion 
of Shoc2 in normal fibroblasts led to a dramatic decrease in ERK1/2 phosphorylation. 
However, in IBMPFD fibroblasts loss of Shoc2 had no effect on ERK1/2 
phosphorylation. Our results indicate that when in complex with Shoc2, VCP facilitates 
tuning of the appropriate levels of ERK1/2 phosphorylation.  
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     (A) 
 
                                        (B) 
 
                  (C)                                                               (D) 
 
Figure 4.1 Shoc2 interacts with VCP. 
(A) A schematic diagram depicting the domains of VCP protein. The position of mutants 
used in this study well as the prey region of VCP (aa180-390) obtained in the yeast two-
hybrid screening is shown. N- N-terminus domain, D1 and D2- ATPase domain. 
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(B) 293FT cells were co-transfected with VCP-GFP, HA-M-Ras or GST-Shoc2. VCP-
GFP and HA-M-Ras were immunoprecipitated and analyzed by immunoblotting using 
anti-HA, -GFP or -GST antibodies.   
(C) Co-immunoprecipitation of endogenous Shoc2, VCP and PSMC5 and ectopically 
expressed YFP-M-Ras. Shoc2, VCP, PSMC5, and M-Ras antibodies were used to detect 
VCP, PSMC5 and M-Ras in Shoc2 immunoprecipitates, and in total lysates of 293FT 
cells. 
(D) GFP-tagged VCP was immunoprecipitated from Cos cells depleted of endogenous 
Shoc2 and stably expressing either YFP-tagged Shoc2 or 7KR mutant Shoc2. VCP and 
Shoc2 were detected in GFP immunoprecipitates and lysates using anti-VCP and anti-
Shoc2 antibodies. 
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         (A) 
 
(B)                                                               (C)      
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(D)                                                                        (E) 
 
 
Figure 4.2 Mapping the interacting domains of VCP and Shoc2.  
(A) Schematic representation of the Shoc2 truncated mutants. LRR, leucine-rich repeats. 
(B) HEK 293FT cells were co-transfected with HA-VCP and Shoc2-tRFP truncated 
mutants depicted in (A). HA-VCP was immunoprecipitated and immunoprecipitates were 
analyzed by immunoblotting using anti-HA and -RFP antibodies. 
(C and D) HEK 293FT cells were co-transfected with VCP-GFP and Shoc2-GST WT or 
truncated mutant LRR12-14 (C), or Δ12-14 (D) depicted in (A). GST-Shoc2 was 
immunoprecipitated and analyzed by immunoblotting using anti-GST and -VCP 
antibodies.  
(E) HEK 293FT cells were co-transfected with GST-Shoc2 (WT or Δ12-14) and HA-
tagged HECT domain of HUWE1. GST-Shoc2 was immunoprecipitated and 
immunoprecipitates were analyzed by immunoblotting using anti-GST and -HA 
antibodies.   
 
(Panel (D) and (E) were generated by EunRyoung Jang) 
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(A)                              (B)                           (C) 
 
(D)                                (E)                                                                 (F)   
 
Figure 4.3. VCP is in complex with Shoc2 on endosomes. 
(A) Post-nuclear supernatants (PNS) from Cos 1 cells were layered on 8-42% sucrose 
gradients and subjected to ultracentrifugation. The indicated proteins were identified by 
immunoblotting (IB) using specific antibodies in crude endosome (CE) or Golgi and 
endoplasmic reticulum (G/ER) fractions. 
(B) VCP was immunoprecipitated from the crude endosomal fraction and analyzed by 
using specific anti-VCP and Shoc2 antibodies.  
(C) Cos-SR cells expressing VCP-GFP (WT or QQ mutant) and GST-PSMC5 were 
fixed, immunostained for GST, followed by immunofluorescence microscopy. Insets 
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show high magnification images of the region indicated by white rectangles. Scale bars: 
10 μm.  
(D) Shoc2 was immunoprecipitated from Cos-SR cells depleted of endogenous Shoc2 and 
stably expressing WT or S2G mutant Shoc2-tRFP. The immunoprecipitates were analyzed 
with anti-VCP, and -Shoc2 antibodies.  
(E) Cos1 cells stably expressing the Shoc2-S2G mutant (Shoc2-S2G-tR) were transfected 
with GST–PSMC5 and VCP-GFP. GST–PSMC5 was immunostained with anti-GST 
antibody. Cells were fixed and followed by immunofluorescence microscopy. Insets show 
high magnification images of the regions of the cell indicated by white rectangles. Scale 
bars: 10 µm.  
(F) Cos1 cells depleted of endogenous Shoc2 and stably expressing either full-length 
Shoc2-tRFP (WT) or the mutant of Shoc2 (Δ21-C) were transfected with VCP-GFP. Shoc2 
was immunoprecipitated (IP) using anti-RFP antibodies. The immunoprecipitates were 
analyzed by immunoblotting (IB) using anti-RFP and -GFP antibodies.  
 
(Panel (D) and (F) were generated by EunRyoung Jang) 
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(A) 
 
           (B) 
 
 
Figure 4.4 Endosomal distribution of the Shoc2 7KR mutant.  
(A) Post-nuclear supernatants (PNS) from Cos1 cells stably expressing either WT Shoc2-
YFP or the Shoc2-7KR mutant were layered on 8-42% sucrose gradients and subjected to 
ultracentrifugation to collect crude endosomal subcellular fractions (CE). Western blot 
analysis was performed and the expression of the indicated proteins was analyzed using 
specific antibodies.   
(B) Cos1 cells stably expressing either WT Shoc2-YFP or the Shoc2-7KR mutant were 
transiently transfected with GST-PSMC5 and imaged with fluorescence microscope.  
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Figure 4.5 VCP does not regulate degradation of Shoc2 and Shoc2’s interacting partners.  
Cos 1 cells were treated with the vehicle (DMSO) or two different doses of VCP-ATPase 
inhibitor CB-5083 for 48 h and subjected to western blot analysis. Blots were probed for 
RAF-1, Shoc2, PSMC5, and GAPDH.  
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          (A)                                                      (B) 
 
           (C)                                                                       (D) 
 
Figure 4.6 ATPase activity of VCP is necessary to modulate the interaction of Shoc2 
with HUWE1.   
(A) Endogenous Shoc2 was immunoprecipitated from HEK 293FT cells transfected with 
wild-type (WT) or catalytically inactive (QQ) mutant of VCP-GFP using anti-Shoc2 
antibody. The immunoprecipitates were analyzed by immunoblotting using anti-GFP and 
-Shoc2 antibodies.  
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(B) HEK 293FT cells were co-transfected with VCP-GFP and GST-Shoc2. Cells were 
then treated with the vehicle (DMSO) or 5 µM of CB-5083 for 4 hr. GST-Shoc2 
immunoprecipitates were analyzed using anti-GST and -GFP antibody antibodies.  
(C) Endogenous Shoc2 was immunoprecipitated from Cos1 cells treated with vehicle 
(DMSO) or 5 µM of CB-5083 for 4 hr. The immunoprecipitates were analyzed by 
immunoblotting using anti-VCP, -HUWE1, RAF-1, -Shoc2, and -PSMC5 antibodies.   
(D) GST-Shoc2 was immunoprecipitated from HEK 293FT cells co-transfected with 
VCP-GFP and GST-Shoc2 and depleted in HUWE1. The immunoprecipitates were 
analyzed using anti-GFP, and -GST antibodies.  
 
(Panel (A), (C) and (D) were generated by EunRyoung Jang) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
117 
 
(A)                                (B)                                (C) 
 
 
(D)                          (E)                            (F)                                        (G)       
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Figure 4.7 VCP controls levels of ubiquitination of Shoc2 and affects RAF-1/ERK1/2 
activation.  
(A-B) Endogenous Shoc2 (A) or RAF-1 (B) were immunoprecipitated from denatured 
cell lysates of Cos1 cells treated with 5 µM of CB-5083 for 4 h. Shoc2 and RAF-1 
ubiquitination was detected by immunoblotting using anti-ubiquitin (Ub) antibody.  
(C) Cos1 cells were serum-starved for 16 h, treated with 5 µM of CB-5083 for 4 h, and 
then stimulated with EGF (0.2 ng/ml) for 7, 15 and 30 min. Endogenous Shoc2 was 
precipitated from denatured cell lysates using anti-Shoc2 antibodies and its ubiquitination 
was detected with anti-ubiquitin (Ub) antibody. Immunoblots were analyzed with anti-
Shoc2, -Ub, and -pERK1/2 antibodies. The results in each panel are representative of 
those from three independent experiments.  
(D) Crude endosomal (CE) subcellular fractions were prepared from Cos1 cells treated 
with vehicle (DMSO) or 5 µM of CB-5083 for 4 h. Endosomal Shoc2 was 
immunoprecipitated and analyzed using indicated antibodies. Rab5 was used as a loading 
control.  
(E) Shoc2 was precipitated from denatured endosomal fractions prepared in (D) using 
anti-Shoc2 antibodies. Shoc2 ubiquitination was detected with anti-Ub antibody. 
(F) Cos1 cells were transfected with GST-Shoc2 and YFP-RAF-1. At 48 h post-
transfection, the cells were serum-starved for 16 h and treated with vehicle (DMSO) or 5 
µM of CB-5083 for 4 h and then stimulated with EGF (0.2 ng/ml) for 7 min. Shoc2 was 
immunoprecipitated using anti-GST antibody. Immunoblots were analyzed with anti-p-
RAF-1, -RAF-1, -GST, and -pERK1/2 antibodies. Blots from the multiple experiments 
were analyzed. Bars represent the mean ± S.E. (n=3) for pRAF-1 normalized to the value 
for GAPDH in arbitrary units (P<0.01, by Student's t-test).  
The results in each panel are representative of those from three independent experiments. 
 
(Panel (C) and (D) were generated by EunRyoung Jang) 
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Figure 4.8 Ubiquitination of Shoc2 is altered in VCP mutant (E305Q, E578Q) 
expressing Cos1 cells. Endogenous Shoc2 was precipitated from the denatured cell 
lysates of Cos1 cells expressing vector, WT, or R155H mutant of VCP-GFP mutant. 
Shoc2 ubiquitination was detected with anti-Ub antibody. 
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           (A)                                                             (B) 
 
    
  (C) 
 
 
Figure 4.9 Ubiquitination of Shoc2 is altered in fibroblasts from IBMPFD patients. 
(A) Endogenous Shoc2 was precipitated from the denatured cell lysates of Cos1 cells 
expressing WT and R155H mutant of VCP-GFP. Shoc2 ubiquitination was detected with 
anti-Ub antibody. 
121 
 
(B) Endogenous Shoc2 was immunoprecipitated from the denatured lysates of primary 
fibroblast using anti-Shoc2 antibodies. GM23284, GM22600, GM22085 – fibroblasts 
harboring VCP R155H mutation, GM22757- normal control. Shoc2 ubiquitination was 
detected with anti-Ub antibody. pERK1/2 was analyzed using specific pERK1/2 (p42/44) 
antibodies.  
(C) Primary fibroblasts from (B) were transfected with non-targeting (NT) siRNA or 
Shoc2 (siShoc2) siRNAs. Cells were serum-starved for 16 h and then stimulated with 
EGF (0.2 ng/ml) for 0, 10, and 30 min. Immunoblots were analyzed with anti-pERK1/2, -
Shoc2, and -GAPDH antibodies.  Blots from the multiple experiments were analyzed. 
Bars represent the mean ± S.E. (n=3) for pERK1/2 normalized to the value for GAPDH 
in arbitrary units (P<0.01, by Student's t-test).  
The results in each panel are representative of those from three independent experiments.    
 
(Panel (A) and (B) were generated by EunRyoung Jang) 
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Chapter 5 
 
Discussion and Future Directions 
 
The work presented in this dissertation was performed with the goal of defining the 
physiological function of Shoc2-routed ERK1/2 signals in embryonic development and 
revealing new insights into the molecular mechanisms underlying Shoc2-mediated 
ERK1/2 signaling. This dissertation is comprised of two interconnected research projects 
discussed in two separate chapters. In chapter 3, I described the work that utilized a 
zebrafish vertebrate model and demonstrated that Shoc2 is critical in early embryonic 
development and its loss results in a number of developmental deficiencies, including 
profound loss of blood cells and delay in development of multiple neural crest lineages.  
 In chapter 4, I characterized the novel interacting partner within the Shoc2 
scaffolding module, AAA+ ATPase VCP. Studies in this chapter show that VCP activity 
is a critical element in the mechanisms remodeling the Shoc2 signaling complex and fine-
tuning the ERK1/2 signals. Importantly, these studies also demonstrate that the alterations 
in Shoc2 ubiquitination and ERK1/2 phosphorylation are important elements of the 
IBMPFD pathology. 
 
1. The physiological function of Shoc2 in development 
Given the early embryonic lethality of shoc2 knock-out mice and causative effects 
of Shoc2 mutations in NSLH syndrome, we hypothesized that Shoc2 is critical for normal 
development. However, the biological targets of the Shoc2-mediated ERK1/2 signals are 
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not clear. Transient depletion of Shoc2 in zebrafish using shoc2-specific MO allowed us 
to observe the profound effect Shoc2 depletion has on very early developmental stages. 
We found that the depletion of Shoc2 in early stage embryos causes defects in blood cell 
development, vasculature development and ERK1/2 activation. The results obtained 
using MO prompted us to generate a heritable zebrafish shoc2 knockout utilizing the 
most rapidly developing genetic methodology- CRISPR/Cas9 editing. CRISPR/Cas9 
genetic editing can be easily applied  to virtually any genome of interest by a 
customizable short RNA guide targeting Cas9 endonuclease [226]. Using this 
methodology, a number of germline-transmitting CRISPR/Cas9 shoc2 mutant lines were 
successfully generated. In the studies summarized above, I have utilized two genetically-
modified zebrafish lines harboring either 22 bp deletion in exon 2 or 14 bp deletion in 
exon 3. Similar to mice knockouts, our findings demonstrate that a systemic deficit of 
Shoc2 in zebrafish critically impairs a number of developmental functions and is lethal 
[227]. Interestingly, unlike shoc2 knockout mice, our shoc2 CRISPR/Cas9 zebrafish 
knockout did not present with apparent changes in cardiac function or pericardial 
effusions, although further studies are needed to analyze possible subtle heart 
malformations. Yi and colleagues observed that conventional shoc2-/- (sur-8 in mice) 
knockout mice die due to an early stage embryonic lethality and partial absorption of 
mutant embryos at E8.5 [121]. The conditional deletion of the shoc2 gene in endothelial 
cells displayed multiple cardiac defects, smaller body size, subcutaneous edema in their 
dorsal body, fetal lung congestion and did not survive past E14.5. These shoc2-deficient 
mice had abnormalities in transposition of the great arteries, a ventricular septal defect, 
and double outlets of the right ventricle and right aortic arch and defects of heart valve 
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morphogenesis. Surprisingly, no obvious change in the level of activated ERK1/2 or two 
other MAP kinases, JNK and p38, were detected in shoc2 null endothelial cells, possibly 
indicating the non-autonomous role for Shoc2 in the endothelial cells. 
A key finding of this study is that the abrogated expression of Shoc2 in zebrafish 
embryos results in a rapid manifestation of a robust phenotype that exhibits hallmarks of 
human RASopathies, further supporting the likelihood of conservation in Shoc2 signaling 
targets between human and zebrafish. Remarkably, severe edema, anemia, and 
arrhythmia observed in shoc2 null larvae were reminiscent of fetal hydrops- a serious 
fetal condition previously reported in several cases of newborns heterozygous for the 
S2G missense mutation in Shoc2. In patients molecularly diagnosed with Shoc2’s NSLH 
mutation, fetal hydrops presented as fluid accumulation in fetal compartments, pleural 
and pericardial effusion, skin edema, leukocytosis, and thrombocytopenia [123, 166, 
228].  
Craniofacial defects detected in Shoc2 null larvae are another well-recognized 
component of the pleiotropic spectrum of RASopathy phenotypes [229]. The striking 
abnormalities in the development of cartilage, bone ossification, and the patterning of 
pigment cells in shoc2 null zebrafish larvae indicate an essential role for Shoc2 in the 
specification of neural crest-derived tissues. In addition to craniofacial cartilage, bone 
and melanocytes, smooth muscle, blood vessels, peripheral and enteric neurons, and glia 
are all derived from a temporary group of highly migratory multipotent stem cells that 
delaminate from the neural tube early in embryogenesis [230, 231]. Importantly, several 
of the RASopathy hallmarks, such as craniofacial birth defects are usually attributed to 
the defects in neural crest cell development. Augmented expression of the transcription 
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factor foxd3 found in shoc2 knockouts provides insights into the possible underlying 
mechanisms downstream of the Shoc2-ERK1/2 module and is in-line with the canonical 
function of the Ras/ERK1/2 pathway in neural crest specification and migration [232]. 
High levels of sox10 or foxD3 in embryonic stem cells and neural crest cells have been 
shown to promote multi-potentiality and the levels of these transcription factors change 
dramatically with cell specification [233-235]. Hence, it is possible that suppression of 
Shoc2-mediated ERK1/2 signals promotes the maintenance of pluripotent progenitor 
cells due to increased foxD3 levels, or other related transcription factors, consequently 
delaying neural crest differentiation and migration. Interestingly, lentiviral depletion of 
Shoc2 in neuronal progenitor cells (NPCs) resulted in misbalanced differentiation and 
proliferation of NPCs [115]. Although these studies did not formally demonstrate a 
requirement for Shoc2-ERK1/2 activity in stem cell specification, they showed that 
Shoc2 may act as an anti-differentiation factor that may regulate ERK1/2 signals 
controlling NPCs for proliferation and self-renewal. However, other Shoc2-ERK1/2 
dependent mechanisms, such as selective integration of signals mediated by BMP, TGFβ, 
FGF or EGF cannot be excluded [236]. Even though several signaling pathways are 
involved in the development of neural crest-derived tissues [236], our data indicate that 
the changes observed in shoc2 null animals attest to a lack of functional redundancy with 
other members of the ERK1/2 pathway and/or contribute to the expression of different 
sets of transcriptional downstream targets. Our data in Figure 3.23 show that shoc2 is 
highly expressed in sox10-positive cells, indicating its cell autonomous functions in 
neural crest cells. Future studies in cells isolated from neural crest lineages will facilitate 
the identification of molecules upstream and downstream of the Shoc2-ERK1/2 module 
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and are likely to reveal novel functions of Shoc2 in neural crest development. The exact 
details of how Shoc2-ERK1/2 signals affect neural crest specification remain to be 
elucidated. Future studies utilizing CRISPR/Cas9 mutants transgenic for the neural crest 
markers sox10:RFP or foxD3:GFP  will help  determine the Shoc2-ERK1/2 signals 
regulating motility of the neural crest cells or the transcriptional programs regulating their 
specification.   
Occasionally, RASopathy patients are diagnosed with an aggressive 
myeloproliferative disorder resembling a rare hematologic malignancy in children termed 
Juvenile myelomonocytic leukemia (JMML) [237, 238]. Some JMML symptoms such as 
anemia and thrombocytopenia are reminiscent of the robust loss of circulating blood cells 
we observed in the Shoc2 crispants and, based on our data in Figure 3.28, is likely due to 
the autonomous function of Shoc2 in hematopoietic cells.  
The findings that shoc2 crispants did not have a preferential loss of a particular 
blood lineage (Figure 3.30) support our hypothesis that Shoc2-ERK1/2 signals are 
universally critical for the production or expansion of progenitors rather than the 
differentiation of a particular blood lineage at the very early stages of hematopoiesis. The 
balance between primitive erythroid and myeloid cell production is primarily governed 
by equilibrium of the expression of the transcription factor gata-1 and pu.1 [184, 185, 
190, 239]. Loss of gata-1 expression in zebrafish embryos results in transformation of 
erythroid precursors into myeloid precursors with myeloid expansion at the expense of 
total number of erythroid cells [239]. Our data in Figure 3.26 and 3.27, showing that the 
loss of Shoc2 causes a reduction in expression of both gata-1 and pu.1 further supports 
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our hypothesis that Shoc2-ERK1/2 signals are responsible for the production/expansion 
of blood progenitors.  
Based on earlier studies demonstrating that Shoc2 transduces ERK1/2 cell 
motility signals [240], it is tempting to speculate that Shoc2-deficient hematopoietic 
progenitors are impaired in their ability to migrate to the environment that supports their 
maturation. Alternatively, the loss of Shoc2 may abrogate the signals potentiating the 
maturation of these cells. To test this notion, CRISPR/Cas9 mutants transgenic for c-
myb:eGFP or cd41:GFP, markers widely utilized to visualize hematopoietic stem and  
progenitor cells, will be particularly beneficial. These transgenic zebrafish lines will 
allow tracing the development of HSCs in real time as well as the analysis of  
fundamental transcriptional programs of HSCs in shoc2 null fish.  
Alterations in the expression of the Shoc2 binding partners, Ras and RAF-1, in 
zebrafish are found to cause phenotypes partially overlapping with those observed in 
shoc2 mutants [241, 242]. Yet, the robust phenotype observed for shoc2 nulls in which 
expression of Ras and RAF signaling proteins is unaltered suggests that the Shoc2 
scaffold is critical for Ras-RAF signal transmission, underscoring its role as a “master 
organizer” and also emphasizes the critical role of the Shoc2-routed ERK1/2 signal. 
One of the advantages of using zebrafish is the ability to annotate the 
pathogenicity and biological activity of human disease-causing alleles. As a future study, 
it will be interesting to determine the effect of RASopathy mutations and Shoc2 
ubiquitination in zebrafish development. 
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In summary, a novel zebrafish model was developed to identify a previously 
unrecognized role of Shoc2 in vasculogenesis, in the specification of neural crest cells, 
and in hematopoiesis. This study not only emphasizes a critical role for Shoc2 in the 
morphogenesis of embryonic tissues, but also underscores the advantages of our zebrafish 
model for dissecting the contribution of individual regulatory components of the ERK1/2 
pathway. The zebrafish shoc2-/- model will be very instrumental in identifying the 
implications of the multiple Shoc2 protein interactions through in vivo structure-function 
analysis. Our model will further help elucidate molecular mechanisms underlying Shoc2-
related pathologies, help track the molecular changes that take place when Shoc2 is not 
transmitting ERK1/2 signals, as well as determine the roles of target genes downstream 
of the Shoc2 scaffolding module in a number of developmental processes. 
 
2.1 VCP is a part of the Shoc2-Ras-RAF-1 signaling complex 
Studies presented here are the first to identify the AAA+ ATPase VCP as a player 
in the ERK1/2 cascade and provide new insight into the mechanism modulating 
ubiquitination of Shoc2 and RAF-1 and the subsequent transmission of the signals 
through the Shoc2 scaffolding complex. I show compelling evidence that VCP is an 
integral partner in the Shoc2 signaling module. Results in Figure 4.1 and 4.2 demonstrate 
that a pool of endogenous VCP is found in the multimolecular complex with Shoc2 and 
its known molecular partners HUWE1, M-Ras, PSMC5 and RAF-1, and that leucine-rich 
repeats 12 to 14 of Shoc2’s LRR domain are sufficient for the recognition of Shoc2 by 
VCP [110, 111, 116, 119, 120]. This data also shows that VCP is associated with 
ubiquitinated Shoc2 (Figure 4.1.D). Prior work demonstrated that VCP is associated with 
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a set of adaptor proteins that recruit or modify substrates [202, 206-209, 224, 225, 243-
247]. Thus, it is unlikely that VCP recognizes Shoc2 without the assistance of a cofactor. 
Future studies using an unbiased mass-spectrometry approach would be instrumental in 
defining other molecular determinants of the complex, including a cofactor mediating the 
VCP and Shoc2 recognition and, possibly, additional components of the VCP-related 
machinery in the Shoc2 complex. 
Our findings of overlap in the VCP’s and HUWE1’s Shoc2 recognition site at the 
LRR 12-14 provided a critical clue into the possible function of VCP in the Shoc2 complex, 
implying that VCP might compete with the E3 ligase for Shoc2 binding. Therefore, we 
postulated that in the Shoc2 complex, mechano-activity of VCP is exerted to “sequester” 
the E3 ligase HUWE1 from the Shoc2 scaffolding complex in order to modulate levels of 
the ubiquitin conjugated to Shoc2 and tune the signals transmitted via the Shoc2 module. 
This hypothesis was consistent with the observations that perturbations in ATPase activity 
of VCP lead to changes in the stoichiometric ratio of VCP and HUWE1 in the Shoc2 
complex and altered both levels and dynamics of Shoc2 ubiquitination. This hypothesis is 
also in agreement with the core biochemical activity of VCP to segregate protein 
components from multiprotein complexes or multimolecular structures [196, 197]. The 
precise mechanism by which VCP exerts its “segregase” activity is not known, but the most 
accepted hypothesis is that VCP grabs onto the ubiquitinated polypeptide to be segregated 
and initiates it unfolding. Thus, it is conceivable that in the Shoc2 complex VCP also acts 
as “segregase” that unfolds ubiquitinated substrate. However, which one of the proteins in 
the Shoc2 complex is a “true” substrate that undergoes unfolding is not clear. Along with 
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Shoc2 and RAF-1, the E3 ligase HUWE is also marked by ubiquitin as the HECT domain 
of HUWE1 catalyze self-ubiquitination in the process of Ubiquitin transmission [120].  
Assuming that Shoc2 is the “true” substrate of VCP, a number of outcomes for this 
segregation activity in the complex are possible. For instance, in addition to the 
sequestration of HUWE1 from the complex, Shoc2 unfolding may also result in the loss 
of RAF-1 or in an orientation of RAF-1 that would be unfavorable for signal 
transmission. These scenarios require further studies using methodologies that can 
reconstitute remodeling events of the Shoc2 scaffolding complex in vitro.  Overall, we 
have yet to determine whether VCP-induced changes in the composition of the Shoc2 
complex ultimately lead to changes in Shoc2 conformation, actual dissociation of 
HUWE1 from the complex or other related events of the complex remodeling.  
Irrespective of the specific aspects of the Shoc2 complex remodeling, this study 
provides novel, exciting knowledge on how the ubiquitin machinery regulates signal 
transition. Previous work revealed that ubiquitin conjugates are utilized to control the 
Ras-ERK1/2 signal transduction differentially [217]. Ubiquitination stabilizes the 
association of H-Ras with endosomes and its ability to activate the ERK1/2 pathway 
[248]. K-Ras and H-Ras are each shown to be activated by mono-ubiquitination but via 
distinct molecular mechanisms. While mono-ubiquitination of K-Ras has an inhibitory 
effect on GAP-mediated hydrolysis, mono-ubiquitination of H-Ras enhances GTP-GDP 
exchange [248-250]. In addition to studies in the Galperin lab demonstrating that 
ubiquitin conjugates control the activation status of the RAF-1 kinase, others reported 
that RAF-1 stability and degradation are controlled by the ubiquitin-proteasome system 
[120]. Additional equally interesting examples are known, but the comprehensive picture 
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of how ubiquitination is involved in the regulation of the ERK1/2 signaling cascade is far 
from being complete.  
Furthermore, results presented here are in agreement with the earlier observations 
demonstrating that Shoc2 ubiquitination is controlled in a spatially restricted manner 
[116]. Much like the E3 ligase HUWE1 and AAA+ ATPase PSMC5, VCP was found in 
complex with wild-type Shoc2 when targeted to the endosomal membranes. In contrast, 
VCP failed to recognize the aberrantly targeted to the plasma membrane Shoc2 S2G 
RASopathy mutant (Figure 4.3.D and E). Inhibition of VCP activity by CB-5083 caused 
an increased ubiquitination of the endosome-localized Shoc2, further emphasizing the 
role endosomes play in supporting the specific micro-environmental requirement for the 
regulation of signaling [96]. MP1/p14 (or LAMTOR2-LAMTOR3), β-arrestin, and 
flotillin-1 are adaptor proteins that utilize endocytic compartments as spatially confined 
intracellular platforms to control both intensity and specificity of signals transduced 
through these complexes [7, 25, 77, 85-89, 251].  
The processing of VCP substrates is contingent on the binding of K48- and K11-
conjugated ubiquitin chains by VCP and/or its adaptor [252]. The Galperin lab previously 
showed that Shoc2 contains K48- and K-63 ubiquitin chains [120]. Further work in vitro 
and in vivo studies are needed to determine the exact requirements and the nature of 
ubiquitin chains required for the interaction with VCP.  
Importantly, we observed that the inhibition of VCP activity by CB-5083 leads to 
a consistent increase in the phospho-ERK1/2 response to stimuli (Figure 4.7.C and F). 
This prompted a hypothesis that the abnormal function of VCP not only affects the 
regulatory mechanisms within the Shoc2 complex but also deregulates a tightly 
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controlled ERK1/2 signaling network and affects the balance through multiple branches 
of the network.  
 
2.2 Functional implications of VCP-modulated ubiquitination of Shoc2 
Results of this study showed that loss of VCP activity alters the amplitude of 
RAF-1 kinase phosphorylation (Figure 4.7.F), indicating that VCP provides an 
additional control over the amplitude of the ERK1/2 signals transmitted via the Shoc2 
module. Thus, somewhat not surprisingly, we found that in primary fibroblasts collected 
from patients diagnosed with IBMPFD and harboring the R155H mutation, levels of 
Shoc2 ubiquitination and phospho-ERK1/2 were dysregulated. 
VCP has been identified as a causative gene of the dominantly inherited syndrome 
IBMPFD, a neuro-degenerative multi-systemic disorder with cognition defects [196, 
253]. The R155H substitution is the most prevalent, but the precise effect of this hot-spot 
mutation on VCP’s ATPase activity is still a subject for active investigation [216]. 
Several studies argue that this mutation has no effect on VCP structure and is leading to 
an elevated ATPase activity as an indirect consequence of a decoupling of substrate 
binding from mechanochemical transduction in the D2 domain of VCP [254]. Overall, 
the mechanisms of IBMPFD pathogenesis are not fully understood [196, 197]. 
My work shows that Shoc2 accelerates ERK1/2 activity upon pathway stimulation 
in primary fibroblasts obtained from healthy individuals (Figure 4.9.C). However, in 
primary fibroblasts harboring a VCP (R155H) mutation, levels of Shoc2-conjugated 
ubiquitin and phospho-ERK1/2 were elevated (Figure 4.9.C). Importantly, Shoc2 
depletion had no effect on EGF-induced activation of ERK1/2 in IBMPFD, further 
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supporting our hypothesis that Shoc2-ERK1/2 signals are part of a tightly controlled and 
balanced larger signaling network and that deregulation in the Shoc2-ERK1/2 axis 
triggers imbalanced ERK1/2 activity. Importantly, this study is the first to suggest a 
possible involvement of aberrant ERK1/2 signaling in the pathogenesis of IBMPFD. 
Future studies will aid in understanding the full extent of the mechanisms causing this 
disease.  
 
 
Figure 5.1 Schematic model of VCP’s function in Shoc2-mediated ERK1/2 signals.  
HUWE1 mediates ubiquitination of Shoc2 and RAF-1 that negatively regulates the RAF-
1 activity. Subsequently, PSMC5 facilitates the redistribution of the ubiquitinated Shoc2 
complex to endosomes where VCP drives the remodeling of the Shoc2 module by 
disengaging HUWE1 as a matter of “reactivating” the Shoc2 signaling module for the 
next signal transmission.  
 
 
To summarize, we propose a model that is based on what is currently understood 
for the mechanisms modulating the Shoc2-mediated ERK1/2 signals (Figure 5.1). This 
model postulates that ERK1/2 pathway activation is followed by HUWE1-mediated 
ubiquitination of Shoc2 and RAF-1, causing adjustments in the amplitude of ERK1/2 
signaling. Thereafter, PSMC5 facilitates the recruitment of the Shoc2 complex to 
endosomes where VCP possibly sequesters or “segregates” HUWE1 from the Shoc2 
complex, possibly aiding in the “reactivation” of the Shoc2 signaling module.  
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To provide further support for this model, it is necessary to examine the activation of 
RAF-1 that is in complex with Shoc2 on endosomes. Future studies should investigate 
where the Shoc2-Ras-RAF-1 complexes are formed when proteins of the ubiquitin 
machinery (HUWE1, PSMC5, and VCP) incorporate into the complex and what triggers 
the Shoc2-VCP interaction.  
  
In summary, the studies presented in this dissertation identified an unexpected 
physiological role for the Shoc2-transmitted ERK1/2 signals in hematopoiesis and neural 
crest development. They also added another layer to our understanding of the 
mechanisms controlling transmission of the ERK1/2 signals through the Shoc2 
scaffolding complex. Together these results have a potential to open up new avenues for 
the development of better therapeutic strategies for the treatment of RASopathies and 
IBMPFD. 
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Appendix 
List of Acronyms and Abbreviations 
ALM Anterior lateral mesoderm 
AGM Aorta-gonad-mesonephros 
AAA+ ATPase ATPase-associated with diverse cellular activities 
bp Base pair 
JNK c-Jun N-terminal kinase 
CFC Cardio-facio-cutaneous syndrome 
CHT Caudal hematopoietic tissue 
CRISPR Clustered regularly interspaced short palindromic repeats 
Cas9 CRISPR-associated protein 9 
CE Crude endosome 
dpf Days post fertilization 
DNA Deoxyribonucleic acid, 
DA Dorsal aorta 
EEA1 Early endosome antigen 1 
ERAD Endoplasmic reticulum associated protein degradation 
EGFP Enhanced green fluorescent protein  
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
Erbin Erbb2 interacting protein 
EMPs Erythromyeloid progenitors 
ERK Extracellular signal-regulated kinase 
FGF Fibroblast growth factor receptor 
FGFR Fibroblast growth factor receptor 
FACS Fluorescence activated cell sorting 
GST Glutathione-S-transferase  
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
G/ER Golgi/Endoplasmic reticulum 
GFP Green fluorescent protein 
HUWE1 HECT, UBS and WWE domain containing 1 
HA Hemagglutinin 
HSCs Hematopoietic stem cells 
HRMA High resolution melting analysis 
HPLC High-performance liquid chromatography 
hpf Hours post fertilization 
IP Immunoprecipitation 
IBMPFD 
Inclusion body myopathy with paget’s disease of bone and  
frontotemporal dementia 
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ICM Intermediate cell mass 
IQGAP1 IQ motif-containing GTPase activating protein 1 
JMML Juvenile myelomonocytic leukemia 
kDa Kilo dalton 
KSR Kinase suppressor of Ras 
LE/MVBs Late endosomes/Multivesicular bodies 
LRR Leucine-rich repeat 
MP1 MAPK kinase 1 partner 
MAPKAPK MAPK-activated protein kinase 
MAPK Mitogen-activated protein kinase 
MEK Mitogen-activated protein kinase kinase 
MO Morpholino 
NGF Nerve growth factor 
NCCs Neural crest cells 
NF1 Neurofibromatosis type 1 
NS Noonan syndrome 
NSLH Noonan syndrome with loose anagen hair 
NSML Noonan syndrome with multiple lentigines 
PFA Paraformaldehyde 
PTU Phenyl thiourea 
PCR Polymerase chain reaction 
PVC Posterior cardinal vein 
PSMC5 Proteasome 26S subunit ATPase 5 
PP1c Protein phosphatase 1c 
qPCR Quantitative PCR 
RTK Receptor tyrosine kinase 
RFP Red fluorescent protein 
RT-PCR Reverse transcript PCR 
RNA Ribonucleic acid 
SCRIB Scribbled homolog 
sgRNA Single guide RNA 
siRNA Small interfering RNA 
SH2 Src homology 2 
SIV Sub-intestinal vein 
UPS ubiquitin-proteasomal system 
VCP Valosin-containing protein 
VAST Vertebrate automated screening technology 
WT Wild-type 
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